US5994041A
(en)
*
|
1985-04-06 |
1999-11-30 |
Eastman Kodak Company |
Process for buffering concentrated aqueous slurries
|
US5552154A
(en)
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
US5552160A
(en)
*
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
AU642066B2
(en)
*
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
US5399363A
(en)
*
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
SE9101090D0
(sv)
*
|
1991-04-11 |
1991-04-11 |
Astra Ab |
Process for conditioning of water-soluble substances
|
US5766635A
(en)
*
|
1991-06-28 |
1998-06-16 |
Rhone-Poulenc Rorer S.A. |
Process for preparing nanoparticles
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5344640A
(en)
*
|
1991-10-22 |
1994-09-06 |
Mallinckrodt Medical, Inc. |
Preparation of apatite particles for medical diagnostic imaging
|
US5342609A
(en)
*
|
1991-10-22 |
1994-08-30 |
Mallinckrodt Medical, Inc. |
Microfluidization of calcium/oxyanion-containing particles
|
US5407659A
(en)
*
|
1991-10-22 |
1995-04-18 |
Mallinckrodt Medical, Inc. |
Treated calcium/oxyanion-containing particles for medical diagnostic imaging
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
DE69218455T2
(de)
*
|
1991-12-18 |
1997-10-23 |
Minnesota Mining And Mfg. Co., Saint Paul, Minn. |
Aerosolzusammensetzungen für arzneimittelsuspensionen
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
JP4439590B2
(ja)
*
|
1992-06-10 |
2010-03-24 |
エラン ファーマ インターナショナル,リミティド |
表面改質nsaidナノ粒子
|
US5552156A
(en)
*
|
1992-10-23 |
1996-09-03 |
Ohio State University |
Liposomal and micellular stabilization of camptothecin drugs
|
AU660852B2
(en)
*
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
US5298262A
(en)
*
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
US5346702A
(en)
*
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
US5302401A
(en)
*
|
1992-12-09 |
1994-04-12 |
Sterling Winthrop Inc. |
Method to reduce particle size growth during lyophilization
|
US5340564A
(en)
*
|
1992-12-10 |
1994-08-23 |
Sterling Winthrop Inc. |
Formulations comprising olin 10-G to prevent particle aggregation and increase stability
|
US5336507A
(en)
*
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
US5429824A
(en)
*
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5256328A
(en)
*
|
1992-12-16 |
1993-10-26 |
Eastman Kodak Company |
Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
|
US5352459A
(en)
*
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
US5322679A
(en)
*
|
1992-12-16 |
1994-06-21 |
Sterling Winthrop Inc. |
Iodinated aroyloxy esters
|
US5364550A
(en)
*
|
1992-12-16 |
1994-11-15 |
Eastman Kodak Company |
Liquid detergent composition
|
US5326552A
(en)
*
|
1992-12-17 |
1994-07-05 |
Sterling Winthrop Inc. |
Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
|
US5354564A
(en)
*
|
1992-12-18 |
1994-10-11 |
Eastman Kodak Company |
Personal care compositions
|
US6663881B2
(en)
|
1993-01-28 |
2003-12-16 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5916596A
(en)
|
1993-02-22 |
1999-06-29 |
Vivorx Pharmaceuticals, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
FR2702160B1
(fr)
*
|
1993-03-02 |
1995-06-02 |
Biovecteurs As |
Vecteurs particulaires synthétiques et procédé de préparation.
|
US5830436A
(en)
*
|
1993-03-30 |
1998-11-03 |
Duke University |
Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
|
US5840277A
(en)
*
|
1993-03-30 |
1998-11-24 |
Charlotte Hospital Authority |
Treatment of chronic pulmonary inflammation
|
US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5543158A
(en)
*
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
US5635206A
(en)
*
|
1994-01-20 |
1997-06-03 |
Hoffmann-La Roche Inc. |
Process for liposomes or proliposomes
|
EP0678771B1
(en)
*
|
1994-04-18 |
2001-11-21 |
Eastman Kodak Company |
Stable aqueous solid particle dispersions
|
US5468598A
(en)
*
|
1994-04-18 |
1995-11-21 |
Eastman Kodak Company |
Solid particle dispersions for imaging systems
|
US5478705A
(en)
*
|
1994-05-25 |
1995-12-26 |
Eastman Kodak Company |
Milling a compound useful in imaging elements using polymeric milling media
|
US5500331A
(en)
*
|
1994-05-25 |
1996-03-19 |
Eastman Kodak Company |
Comminution with small particle milling media
|
TW384224B
(en)
*
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
US5513803A
(en)
*
|
1994-05-25 |
1996-05-07 |
Eastman Kodak Company |
Continuous media recirculation milling process
|
US5587143A
(en)
*
|
1994-06-28 |
1996-12-24 |
Nanosystems L.L.C. |
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US6007845A
(en)
*
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
DE4440337A1
(de)
*
|
1994-11-11 |
1996-05-15 |
Dds Drug Delivery Services Ges |
Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
|
US5955108A
(en)
*
|
1994-12-16 |
1999-09-21 |
Quadrant Healthcare (Uk) Limited |
Cross-linked microparticles and their use as therapeutic vehicles
|
US6524557B1
(en)
*
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
US5609998A
(en)
*
|
1994-12-29 |
1997-03-11 |
Eastman Kodak Company |
Process for dispersing concentrated aqueous slurries
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
US5585108A
(en)
*
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
US5466440A
(en)
*
|
1994-12-30 |
1995-11-14 |
Eastman Kodak Company |
Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
|
US5628981A
(en)
*
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
US5665331A
(en)
*
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
US5662883A
(en)
*
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
US5716642A
(en)
*
|
1995-01-10 |
1998-02-10 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
|
US5560932A
(en)
*
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
US5569448A
(en)
*
|
1995-01-24 |
1996-10-29 |
Nano Systems L.L.C. |
Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US5520904A
(en)
*
|
1995-01-27 |
1996-05-28 |
Mallinckrodt Medical, Inc. |
Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
|
EP0808154B1
(en)
*
|
1995-02-06 |
2000-12-20 |
Elan Pharma International Limited |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
US5571536A
(en)
*
|
1995-02-06 |
1996-11-05 |
Nano Systems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
US5503723A
(en)
*
|
1995-02-08 |
1996-04-02 |
Eastman Kodak Company |
Isolation of ultra small particles
|
US5665330A
(en)
*
|
1995-02-08 |
1997-09-09 |
Nano Systems Llc |
Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
|
US5622938A
(en)
*
|
1995-02-09 |
1997-04-22 |
Nano Systems L.L.C. |
Sugar base surfactant for nanocrystals
|
US5518738A
(en)
*
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
US5591456A
(en)
*
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
US5573783A
(en)
*
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
US5510118A
(en)
*
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
US5543133A
(en)
*
|
1995-02-14 |
1996-08-06 |
Nanosystems L.L.C. |
Process of preparing x-ray contrast compositions containing nanoparticles
|
WO1996025181A1
(en)
*
|
1995-02-14 |
1996-08-22 |
Nanosystems L.L.C. |
Process of preparing lymphography contrast agents
|
US5580579A
(en)
*
|
1995-02-15 |
1996-12-03 |
Nano Systems L.L.C. |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
|
US5747001A
(en)
*
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
AU4990696A
(en)
*
|
1995-02-24 |
1996-09-11 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
US5565188A
(en)
*
|
1995-02-24 |
1996-10-15 |
Nanosystems L.L.C. |
Polyalkylene block copolymers as surface modifiers for nanoparticles
|
US5736156A
(en)
*
|
1995-03-22 |
1998-04-07 |
The Ohio State University |
Liposomal anf micellular stabilization of camptothecin drugs
|
US5605696A
(en)
*
|
1995-03-30 |
1997-02-25 |
Advanced Cardiovascular Systems, Inc. |
Drug loaded polymeric material and method of manufacture
|
US6428771B1
(en)
*
|
1995-05-15 |
2002-08-06 |
Pharmaceutical Discovery Corporation |
Method for drug delivery to the pulmonary system
|
IL118088A0
(en)
*
|
1995-06-07 |
1996-08-04 |
Anzon Inc |
Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
|
EP0752245B1
(en)
*
|
1995-07-05 |
2002-05-22 |
European Community |
Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
|
BE1009856A5
(fr)
*
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6391338B1
(en)
*
|
1995-09-07 |
2002-05-21 |
Biovail Technologies Ltd. |
System for rendering substantially non-dissoluble bio-affecting agents bio-available
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
CA2234957C
(en)
*
|
1995-10-17 |
2006-12-19 |
Inge B. Henriksen |
Insoluble drug delivery
|
US5679138A
(en)
*
|
1995-11-30 |
1997-10-21 |
Eastman Kodak Company |
Ink jet inks containing nanoparticles of organic pigments
|
US5662279A
(en)
*
|
1995-12-05 |
1997-09-02 |
Eastman Kodak Company |
Process for milling and media separation
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
US5968543A
(en)
*
|
1996-01-05 |
1999-10-19 |
Advanced Polymer Systems, Inc. |
Polymers with controlled physical state and bioerodibility
|
US5686133A
(en)
*
|
1996-01-31 |
1997-11-11 |
Port Systems, L.L.C. |
Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
|
JP3178724B2
(ja)
*
|
1996-03-05 |
2001-06-25 |
エイカスフィアー・インコーポレーテッド |
画像化剤として使用するためのミクロカプセル化フッ素化ガス
|
US5611344A
(en)
*
|
1996-03-05 |
1997-03-18 |
Acusphere, Inc. |
Microencapsulated fluorinated gases for use as imaging agents
|
JP4024302B2
(ja)
*
|
1996-05-17 |
2007-12-19 |
クアドラント、 ドラッグ、 デリバリー、 リミテッド |
微粒子および創傷治療におけるその用途
|
US6652837B1
(en)
*
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
USRE37053E1
(en)
|
1996-05-24 |
2001-02-13 |
Massachusetts Institute Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US20020052310A1
(en)
*
|
1997-09-15 |
2002-05-02 |
Massachusetts Institute Of Technology The Penn State Research Foundation |
Particles for inhalation having sustained release properties
|
DE69734060T2
(de)
|
1996-05-24 |
2006-06-29 |
Angiotech Pharmaceuticals, Inc., Vancouver |
Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
|
US5874064A
(en)
*
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6503480B1
(en)
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5726154A
(en)
*
|
1996-06-28 |
1998-03-10 |
University Of Utah Research Foundation |
Stabilization and oral delivery of calcitonin
|
US5837221A
(en)
*
|
1996-07-29 |
1998-11-17 |
Acusphere, Inc. |
Polymer-lipid microencapsulated gases for use as imaging agents
|
US5935890A
(en)
|
1996-08-01 |
1999-08-10 |
Glcc Technologies, Inc. |
Stable dispersions of metal passivation agents and methods for making them
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7060253B1
(en)
*
|
1996-09-20 |
2006-06-13 |
Mundschenk David D |
Topical formulations and delivery systems
|
GB9622173D0
(en)
*
|
1996-10-24 |
1996-12-18 |
Glaxo Group Ltd |
Particulate Products
|
US6515016B2
(en)
|
1996-12-02 |
2003-02-04 |
Angiotech Pharmaceuticals, Inc. |
Composition and methods of paclitaxel for treating psoriasis
|
FR2758459B1
(fr)
*
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
US5993856A
(en)
*
|
1997-01-24 |
1999-11-30 |
Femmepharma |
Pharmaceutical preparations and methods for their administration
|
US6416778B1
(en)
*
|
1997-01-24 |
2002-07-09 |
Femmepharma |
Pharmaceutical preparations and methods for their regional administration
|
WO1998035666A1
(en)
*
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
US6045829A
(en)
*
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
CO4920215A1
(es)
*
|
1997-02-14 |
2000-05-29 |
Novartis Ag |
Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5989591A
(en)
*
|
1997-03-14 |
1999-11-23 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US6193954B1
(en)
*
|
1997-03-21 |
2001-02-27 |
Abbott Laboratories |
Formulations for pulmonary delivery of dopamine agonists
|
AU7133898A
(en)
*
|
1997-04-18 |
1998-11-13 |
Vertex Pharmaceuticals Incorporated |
Nanosized aspartyl protease inhibitors
|
WO1998050385A1
(en)
|
1997-05-08 |
1998-11-12 |
Merck Sharp & Dohme Limited |
SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
|
IT1292142B1
(it)
*
|
1997-06-12 |
1999-01-25 |
Maria Rosa Gasco |
Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
|
AU8145198A
(en)
*
|
1997-06-16 |
1999-01-04 |
Vertex Pharmaceuticals Incorporated |
Methods of increasing the bioavailability of stable crystal polymorphs of a compound
|
CN101579335B
(zh)
|
1997-06-27 |
2016-08-03 |
阿布拉科斯生物科学有限公司 |
药剂的制剂及其制备和应用方法
|
KR100904931B1
(ko)
*
|
1997-06-27 |
2009-06-29 |
아브락시스 바이오사이언스, 엘엘씨 |
나노 입자 및 그의 제조 방법
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6946117B1
(en)
*
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6919070B1
(en)
*
|
1997-10-17 |
2005-07-19 |
Zakrytoe Aktsionernoe Obschestvo “OSTIM” |
Stomatic composition
|
UA72189C2
(uk)
*
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
GB9726543D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel compositions
|
US6086376A
(en)
*
|
1998-01-30 |
2000-07-11 |
Rtp Pharma Inc. |
Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
|
YU46500A
(sh)
|
1998-02-25 |
2002-11-15 |
Merck Charp & Dohme Limited |
Substituisani 1,2,4-triazolo /3,4-a/piridazin
|
ZA991922B
(en)
*
|
1998-03-11 |
1999-09-13 |
Smithkline Beecham Corp |
Novel compositions of eprosartan.
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
WO1999049846A2
(en)
*
|
1998-03-30 |
1999-10-07 |
Rtp Pharma Inc. |
Compositions containing microparticles of water-insoluble substances and method for their preparation
|
US6337092B1
(en)
|
1998-03-30 |
2002-01-08 |
Rtp Pharma Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
JP2002516267A
(ja)
|
1998-05-29 |
2002-06-04 |
アールティーピー・ファーマ・インコーポレーテッド |
熱的に保護された微粒子組成物及びその最終蒸気滅菌
|
US6153225A
(en)
*
|
1998-08-13 |
2000-11-28 |
Elan Pharma International Limited |
Injectable formulations of nanoparticulate naproxen
|
US6956021B1
(en)
*
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US6165506A
(en)
*
|
1998-09-04 |
2000-12-26 |
Elan Pharma International Ltd. |
Solid dose form of nanoparticulate naproxen
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
JP2002525311A
(ja)
*
|
1998-10-01 |
2002-08-13 |
エラン ファーマ インターナショナル,リミティド |
徐放性ナノ粒子組成物
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
HU230454B1
(hu)
*
|
1998-11-02 |
2016-07-28 |
Alkermes Pharma Ireland Limited |
Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
CN1230162C
(zh)
*
|
1998-11-12 |
2005-12-07 |
史密丝克莱恩比彻姆有限公司 |
改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物
|
US6969529B2
(en)
*
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
GB9824897D0
(en)
|
1998-11-12 |
1999-01-06 |
Merck Sharp & Dohme |
Therapeutic compounds
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
EE05190B1
(et)
|
1998-11-20 |
2009-08-17 |
Rtp Pharma Inc. |
Dispergeeruvad fosfolipiididega stabiliseeritud mikroosakesed
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
JP4813660B2
(ja)
*
|
1998-11-27 |
2011-11-09 |
ダーウィン ディスカバリー リミテッド |
骨鉱化作用を増加するための組成物および方法
|
DE19856432A1
(de)
*
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
|
DE69901284T2
(de)
|
1999-01-27 |
2002-11-28 |
Idea Ag |
Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
|
SI1031346T1
(en)
|
1999-01-27 |
2002-08-31 |
Idea Ag |
Noninvasive vaccination through the skin
|
US6267985B1
(en)
*
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US7374779B2
(en)
*
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US6270806B1
(en)
*
|
1999-03-03 |
2001-08-07 |
Elan Pharma International Limited |
Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
|
US6267989B1
(en)
*
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
EG23951A
(en)
|
1999-03-25 |
2008-01-29 |
Otsuka Pharma Co Ltd |
Cilostazol preparation
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
WO2000060940A1
(en)
*
|
1999-04-12 |
2000-10-19 |
Dow Agrosciences Llc |
Aqueous dispersions of agricultural chemicals
|
US6491239B2
(en)
|
1999-05-06 |
2002-12-10 |
Eastman Kodak Company |
Process for milling compounds
|
US6309749B1
(en)
|
1999-05-06 |
2001-10-30 |
Eastman Kodak Company |
Ceramic milling media containing tetragonal zirconia
|
US6444223B1
(en)
*
|
1999-05-28 |
2002-09-03 |
Alkermes Controlled Therapeutics, Inc. |
Method of producing submicron particles of a labile agent and use thereof
|
WO2000072973A1
(en)
*
|
1999-06-01 |
2000-12-07 |
Elan Pharma International Ltd. |
Small-scale mill and method thereof
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
US9006175B2
(en)
*
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
ES2569916T3
(es)
|
1999-06-29 |
2016-05-13 |
Mannkind Corporation |
Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
MXPA02000053A
(es)
*
|
1999-07-05 |
2003-07-21 |
Idea Ag |
Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
|
US6576224B1
(en)
*
|
1999-07-06 |
2003-06-10 |
Sinuspharma, Inc. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
FR2795961B1
(fr)
*
|
1999-07-09 |
2004-05-28 |
Ethypharm Lab Prod Ethiques |
Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
|
US7863331B2
(en)
|
1999-07-09 |
2011-01-04 |
Ethypharm |
Pharmaceutical composition containing fenofibrate and method for the preparation thereof
|
US6933318B1
(en)
|
1999-08-12 |
2005-08-23 |
Eli Lilly And Company |
Topical organic ectoparasiticidal formulations
|
US6927210B1
(en)
|
1999-08-12 |
2005-08-09 |
Eli Lilly And Company |
Ectoparasiticidal aqueous suspension formulations of spinosyns
|
JP5046455B2
(ja)
|
1999-08-12 |
2012-10-10 |
イーライ リリー アンド カンパニー |
コンパニオン動物における害虫の経口処置
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
CA2382821A1
(en)
*
|
1999-08-25 |
2001-03-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US20010036481A1
(en)
*
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US6656504B1
(en)
|
1999-09-09 |
2003-12-02 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
|
EP1229931A4
(en)
*
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
|
JP4806507B2
(ja)
|
1999-10-29 |
2011-11-02 |
ユーロ−セルティーク エス.エイ. |
制御放出ヒドロコドン処方
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US20030203884A1
(en)
*
|
1999-11-09 |
2003-10-30 |
Pharmacia Corporation |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
US20030096798A1
(en)
*
|
1999-11-09 |
2003-05-22 |
Williams Gordon H. |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
AUPQ441699A0
(en)
|
1999-12-02 |
2000-01-06 |
Eli Lilly And Company |
Pour-on formulations
|
US6251136B1
(en)
|
1999-12-08 |
2001-06-26 |
Advanced Cardiovascular Systems, Inc. |
Method of layering a three-coated stent using pharmacological and polymeric agents
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
DK1175214T3
(da)
*
|
1999-12-08 |
2006-07-17 |
Pharmacia Corp |
Cyclooxygenase-2-hæmmer-kompositioner med hurtig indtræden af terapeutisk virkning
|
CA2362845A1
(en)
*
|
1999-12-08 |
2001-06-14 |
Pharmacia Corporation |
Eplerenone crystalline form
|
US6702849B1
(en)
|
1999-12-13 |
2004-03-09 |
Advanced Cardiovascular Systems, Inc. |
Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
|
US7078057B2
(en)
|
1999-12-20 |
2006-07-18 |
Kerkhof Nicholas J |
Process for producing nanometer particles by fluid bed spray-drying
|
US8771740B2
(en)
*
|
1999-12-20 |
2014-07-08 |
Nicholas J. Kerkhof |
Process for producing nanoparticles by spray drying
|
GB9930562D0
(en)
*
|
1999-12-23 |
2000-02-16 |
Boc Group Plc |
Partial oxidation of hydrogen sulphide
|
WO2001047495A1
(en)
|
1999-12-23 |
2001-07-05 |
Pfizer Products Inc. |
Pharmaceutical compositions providing enhanced drug concentrations
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
JP2004501068A
(ja)
*
|
2000-01-31 |
2004-01-15 |
コラボレイティヴ・テクノロジーズ・インコーポレーテッド |
界面活性剤を含まない局所用組成物、及びその迅速な調製方法
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
WO2001062893A2
(en)
*
|
2000-02-25 |
2001-08-30 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
CA2400172C
(en)
*
|
2000-02-28 |
2010-04-20 |
Genesegues, Inc. |
Nanocapsule encapsulation system and method
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AUPQ634300A0
(en)
*
|
2000-03-20 |
2000-04-15 |
Eli Lilly And Company |
Synergistic formulations
|
US7153525B1
(en)
*
|
2000-03-22 |
2006-12-26 |
The University Of Kentucky Research Foundation |
Microemulsions as precursors to solid nanoparticles
|
US7119085B2
(en)
*
|
2000-03-23 |
2006-10-10 |
Elan Pharmaceuticals, Inc. |
Methods to treat alzheimer's disease
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
GB0009773D0
(en)
*
|
2000-04-19 |
2000-06-07 |
Univ Cardiff |
Particulate composition
|
CA2407027C
(en)
|
2000-04-20 |
2011-02-15 |
Rtp Pharma Inc. |
Improved water-insoluble drug particle process
|
DK1280520T4
(en)
|
2000-05-10 |
2018-06-25 |
Novartis Ag |
Phospholipid based powders for drug delivery
|
ES2303527T3
(es)
|
2000-05-10 |
2008-08-16 |
Jagotec Ag |
Procedimiento de molienda.
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
MY120279A
(en)
|
2000-05-26 |
2005-09-30 |
Pharmacia Corp |
Use of a celecoxib composition for fast pain relief
|
ES2333579T3
(es)
*
|
2000-06-20 |
2010-02-24 |
Corixa Corporation |
Proteinas de fusion de mycobacterium tuberculosis.
|
MXPA02012271A
(es)
*
|
2000-06-27 |
2004-09-06 |
Genelabs Tech Inc |
Nuevos compuestos que poseen actividad antibacteriana, antifungal o antitumor.
|
AR029540A1
(es)
|
2000-06-28 |
2003-07-02 |
Corixa Corp |
COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
JP2004502665A
(ja)
|
2000-06-30 |
2004-01-29 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病を治療する化合物
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
IN192160B
(zh)
*
|
2000-07-17 |
2004-02-28 |
Ranbaxy Lab |
|
US6656505B2
(en)
*
|
2000-07-21 |
2003-12-02 |
Alpharma Uspd Inc. |
Method for forming an aqueous flocculated suspension
|
ES2265437T3
(es)
*
|
2000-07-27 |
2007-02-16 |
Pharmacia Corporation |
Terapia de combinacion antagonista epoxi-esteroidal de aldosterona y antagonista beta-adrenergico para tratamiento de la insuficiencia cardiaca congestiva.
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
ES2251505T3
(es)
*
|
2000-08-28 |
2006-05-01 |
Pharmacia Corporation |
Uso de un antagonista del receptor de aldosterona para mejorar la funcion cognoscitiva.
|
DE60137943D1
(de)
|
2000-08-31 |
2009-04-23 |
Jagotec Ag |
Gemahlene partikel
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
CN101317825A
(zh)
|
2000-10-30 |
2008-12-10 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
US8551526B2
(en)
*
|
2000-11-03 |
2013-10-08 |
Board Of Regents, The University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US6756062B2
(en)
|
2000-11-03 |
2004-06-29 |
Board Of Regents University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US20030198679A1
(en)
*
|
2000-11-08 |
2003-10-23 |
Kundu Subhas C. |
Flocculated pharmaceutical suspensions and methods for actives
|
IL155696A0
(en)
*
|
2000-11-09 |
2003-11-23 |
Neopharm Inc |
Sn-38 lipid complexes and methods of use
|
GB0028583D0
(en)
*
|
2000-11-23 |
2001-01-10 |
Merck Sharp & Dohme |
Therapeutic compounds
|
WO2002043700A2
(en)
|
2000-11-30 |
2002-06-06 |
Vectura Limited |
Particles for use in a pharmaceutical composition
|
EP3269360A1
(en)
|
2000-11-30 |
2018-01-17 |
Vectura Limited |
Method of making particles for use in a pharmaceutical composition
|
JP2004518642A
(ja)
*
|
2000-12-06 |
2004-06-24 |
ファルマシア・コーポレーション |
ラボラトリースケールの微粉砕化プロセス
|
CN1487936A
(zh)
*
|
2000-12-11 |
2004-04-07 |
����ҩƷ��ҵ��ʽ���� |
具有改进吸收性能的药物组合物
|
DE10063092A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskalige Materialien in Hygiene-Produkten
|
DE10063090A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskaliges ZnO in Hygiene-Produkten
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6623761B2
(en)
|
2000-12-22 |
2003-09-23 |
Hassan Emadeldin M. |
Method of making nanoparticles of substantially water insoluble materials
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US6607784B2
(en)
*
|
2000-12-22 |
2003-08-19 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
CN100512798C
(zh)
*
|
2000-12-22 |
2009-07-15 |
巴克斯特国际公司 |
亚微米颗粒悬浮液制备方法
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20020198254A1
(en)
*
|
2000-12-27 |
2002-12-26 |
Velligan Mark D. |
Polyamide analogs
|
WO2002053190A2
(en)
|
2000-12-29 |
2002-07-11 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having sustained release properties
|
US20020141946A1
(en)
*
|
2000-12-29 |
2002-10-03 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
US20030125236A1
(en)
*
|
2000-12-29 |
2003-07-03 |
Advenced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
FI20010115A0
(fi)
*
|
2001-01-18 |
2001-01-18 |
Orion Corp |
Menetelmä nanopartikkelien valmistamiseksi
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CA2434430A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
CZ20032031A3
(cs)
*
|
2001-01-26 |
2003-12-17 |
Schering Corporation |
Farmaceutický prostředek
|
NZ542090A
(en)
*
|
2001-01-26 |
2006-09-29 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
MXPA03006727A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
|
SK288217B6
(sk)
*
|
2001-01-26 |
2014-08-05 |
Merck Sharp & Dohme Corp. |
Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
|
EP1785144A3
(en)
*
|
2001-01-26 |
2007-05-23 |
Shering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
WO2002060411A2
(en)
*
|
2001-01-30 |
2002-08-08 |
Board Of Regents University Of Texas System |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
US20040022861A1
(en)
*
|
2001-01-30 |
2004-02-05 |
Williams Robert O. |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
US6497896B2
(en)
|
2001-02-12 |
2002-12-24 |
Supergen, Inc. |
Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
|
US20020150615A1
(en)
*
|
2001-02-12 |
2002-10-17 |
Howard Sands |
Injectable pharmaceutical composition comprising microdroplets of a camptothecin
|
US6509027B2
(en)
|
2001-02-12 |
2003-01-21 |
Supergen, Inc. |
Injectable pharmaceutical composition comprising coated particles of camptothecin
|
JP3386052B2
(ja)
*
|
2001-02-13 |
2003-03-10 |
トヨタ自動車株式会社 |
ポンプ装置
|
SK287582B6
(sk)
|
2001-02-14 |
2011-03-04 |
Tibotec Pharmaceuticals Ltd. |
2-(Substituovaná amino)benztiazolsulfonamidová zlúčenina, spôsob jej prípravy, použitie a farmaceutická zmes s jej obsahom
|
ATE357216T1
(de)
*
|
2001-02-22 |
2007-04-15 |
Jagotec Ag |
Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
|
US20030055067A1
(en)
*
|
2001-04-03 |
2003-03-20 |
Schering Corporation |
Antifungal composition with enhanced bioavailability
|
AU2002245979A1
(en)
*
|
2001-04-05 |
2002-10-21 |
Universite Laval |
Process for making protein delivery matrix and uses thereof
|
EP1397367A2
(en)
|
2001-04-09 |
2004-03-17 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US20020192280A1
(en)
*
|
2001-05-01 |
2002-12-19 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
US20030157161A1
(en)
*
|
2001-05-01 |
2003-08-21 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
ITMO20010086A1
(it)
*
|
2001-05-08 |
2002-11-08 |
Worgas Bruciatori Srl |
Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
|
EP1988097A1
(en)
|
2001-05-09 |
2008-11-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
WO2002092595A1
(en)
|
2001-05-11 |
2002-11-21 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors
|
DE10125290B4
(de)
*
|
2001-05-15 |
2005-04-14 |
Siemens Ag |
Verfahren zum Aufbereiten von Nano-Dispersanten
|
CN1533304A
(zh)
*
|
2001-05-23 |
2004-09-29 |
纳幕尔杜邦公司 |
高压介质磨
|
AR038956A1
(es)
*
|
2001-05-25 |
2005-02-02 |
Schering Corp |
Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
ATE401959T1
(de)
*
|
2001-06-05 |
2008-08-15 |
Elan Pharma Int Ltd |
Mahlvorrichtung und verfahren zu deren betrieb
|
US6730319B2
(en)
|
2001-06-06 |
2004-05-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical compositions having depressed melting points
|
US20040173146A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US20040173147A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US6962715B2
(en)
*
|
2001-10-24 |
2005-11-08 |
Hewlett-Packard Development Company, L.P. |
Method and dosage form for dispensing a bioactive substance
|
CA2450205A1
(en)
|
2001-06-13 |
2002-12-19 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
GB0114532D0
(en)
*
|
2001-06-14 |
2001-08-08 |
Jagotec Ag |
Novel compositions
|
EP1269994A3
(en)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
EP1401399A2
(en)
*
|
2001-06-22 |
2004-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions containing polymer and drug assemblies
|
US20030087308A1
(en)
*
|
2001-06-22 |
2003-05-08 |
Elan Pharma International Limited |
Method for high through put screening using a small scale mill or microfluidics
|
US7758890B2
(en)
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
WO2003002122A1
(en)
*
|
2001-06-27 |
2003-01-09 |
Elan Pharmaceuticals, Inc. |
Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
|
US7053109B2
(en)
*
|
2001-07-10 |
2006-05-30 |
Pharmacia & Upjohn Company |
Aminediols for the treatment of Alzheimer's disease
|
EP1406617A1
(en)
*
|
2001-07-10 |
2004-04-14 |
Elan Pharmaceuticals, Inc. |
Diaminediols for the treatment of alzheimer's disease
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
US20030220310A1
(en)
*
|
2001-07-27 |
2003-11-27 |
Schuh Joseph R. |
Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
|
US20080305173A1
(en)
*
|
2001-07-31 |
2008-12-11 |
Beuford Arlie Bogue |
Amorphous drug beads
|
IL160103A0
(en)
*
|
2001-08-06 |
2004-06-20 |
Astrazeneca Ab |
Aqueous dispersion comprising stable nanoparticles of a water-insoluble active substance and an excipient like middle chain triglycerides (mct)
|
GB0119480D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Jagotec Ag |
Novel compositions
|
MY169670A
(en)
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
CA2458889C
(en)
*
|
2001-08-29 |
2011-06-21 |
Dow Global Technologies Inc. |
A process for preparing crystalline drug particles by means of precipitation
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
WO2003024223A1
(en)
*
|
2001-09-17 |
2003-03-27 |
Eli Lilly And Company |
Pesticidal formulations
|
WO2003024425A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Elan Pharma International, Ltd. |
Nanoparticulate insulin formulations
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
PT1427409E
(pt)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
|
CA2460340C
(en)
*
|
2001-09-21 |
2011-02-15 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
JP2005529060A
(ja)
*
|
2001-09-25 |
2005-09-29 |
ファルマシア コーポレイション |
N−(2−ヒドロキシアセチル)−5−(4−ピペリヂル)−4−(4−ピリミヂニル)−3−(4−クロロフェニル)ピラゾールの固体形態
|
IL160570A0
(en)
|
2001-09-26 |
2004-07-25 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7544681B2
(en)
*
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
US20050233003A1
(en)
*
|
2001-09-28 |
2005-10-20 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
|
US20050227911A1
(en)
*
|
2001-09-28 |
2005-10-13 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
|
US6878693B2
(en)
*
|
2001-09-28 |
2005-04-12 |
Solubest Ltd. |
Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
|
US20050191359A1
(en)
*
|
2001-09-28 |
2005-09-01 |
Solubest Ltd. |
Water soluble nanoparticles and method for their production
|
WO2003055469A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Celator Technologies Inc. |
Improved polymer-lipid delivery vehicles
|
CA2462851A1
(en)
|
2001-10-04 |
2003-04-10 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamines
|
AU2002334939A1
(en)
*
|
2001-10-12 |
2003-04-22 |
Eugene R. Cooper |
Compositions having a combination of particles for immediate release and for controlled release
|
EP1478343B1
(en)
*
|
2001-10-15 |
2017-03-22 |
Crititech, Inc. |
Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
TWI330183B
(zh)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
CA2465793A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Taffy Williams |
Methods for vascular imaging using nanoparticulate contrast agents
|
IL161881A0
(en)
*
|
2001-11-08 |
2005-11-20 |
Upjohn Co |
N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
|
US7700851B2
(en)
*
|
2001-11-13 |
2010-04-20 |
U.S. Smokeless Tobacco Company |
Tobacco nicotine demethylase genomic clone and uses thereof
|
MXPA04004713A
(es)
*
|
2001-11-19 |
2005-08-16 |
Pharmacia & Up John Company Ll |
Aminoides utiles en el tratamiento de la enfermedad de alzheimer.
|
ES2415654T3
(es)
*
|
2001-11-20 |
2013-07-26 |
Civitas Therapeutics, Inc. |
Composiciones particuladas mejoradas para suministro pulmonar
|
GB0127805D0
(en)
*
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
US20030129250A1
(en)
*
|
2001-11-20 |
2003-07-10 |
Advanced Inhalation Research Inc. |
Particulate compositions for improving solubility of poorly soluble agents
|
UA76810C2
(uk)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
EP1581119B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
WO2003053411A1
(en)
|
2001-12-19 |
2003-07-03 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
CA2471400A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Femmepharma, Inc. |
Vaginal delivery of drugs
|
ATE516029T1
(de)
|
2001-12-21 |
2011-07-15 |
Tibotec Pharm Ltd |
Sulfonamide die ein heterozyklus-substituiertes phenyl enthalten als broadspectrum-hiv-protease- inhibitoren
|
US20030235619A1
(en)
*
|
2001-12-21 |
2003-12-25 |
Christine Allen |
Polymer-lipid delivery vehicles
|
AU2002364209A1
(en)
*
|
2001-12-26 |
2003-07-24 |
Genelabs Technologies, Inc. |
Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
CA2470533A1
(en)
*
|
2002-01-14 |
2003-07-24 |
Dow Global Technologies Inc. |
Drug nanoparticles from template emulsions
|
JP2005522424A
(ja)
|
2002-02-01 |
2005-07-28 |
ファイザー・プロダクツ・インク |
コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
|
DK1478648T3
(da)
|
2002-02-01 |
2014-07-28 |
Ariad Pharma Inc |
Phosphorholdige forbindelser og anvendelser deraf
|
JP4598399B2
(ja)
*
|
2002-02-04 |
2010-12-15 |
エラン ファーマ インターナショナル,リミティド |
表面安定剤としてリゾチームを有するナノ粒子組成物
|
US7026465B2
(en)
*
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
GB0206200D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
EP1800666A1
(en)
*
|
2002-03-20 |
2007-06-27 |
Elan Pharma International Limited |
Nanoparticulate compositions of angiogenesis inhibitors
|
CA2479735C
(en)
*
|
2002-03-20 |
2011-05-17 |
Elan Pharma International Ltd. |
Fast dissolving dosage forms having reduced friability
|
EP1894591B1
(en)
|
2002-03-20 |
2013-06-26 |
MannKind Corporation |
Cartridge for an inhalation apparatus
|
WO2003080024A2
(en)
*
|
2002-03-20 |
2003-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate compositions of map kinase inhibitors
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
ATE343376T1
(de)
*
|
2002-03-20 |
2006-11-15 |
Elan Pharma Int Ltd |
Nanopartikelzusammensetzungen von angiogeneseinhibitoren
|
WO2003082213A2
(en)
*
|
2002-03-28 |
2003-10-09 |
Imcor Pharmaceutical Company |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
DK1494649T3
(da)
*
|
2002-04-12 |
2012-04-10 |
Alkermes Pharma Ireland Ltd |
Nanopartikel-megestrolformuleringer
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
AU2003263024A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Christopher Mcconville |
Process of forming and modifying particles and compositions produced thereby
|
DE10218109A1
(de)
*
|
2002-04-23 |
2003-11-20 |
Jenapharm Gmbh |
Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
|
US7262208B2
(en)
*
|
2002-04-30 |
2007-08-28 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of Alzheimer's disease
|
CA2484637A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Elan Pharma International Ltd. |
Nanoparticulate nystatin formulations
|
ES2292976T3
(es)
|
2002-05-17 |
2008-03-16 |
Tibotec Pharmaceuticals Ltd. |
Inhibidores de amplio espectro de tipo bencisoxazol-sulfonamida sustituida de la proteasa del vih.
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
DE60328486D1
(de)
*
|
2002-05-24 |
2009-09-03 |
Angiotech Int Ag |
Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
|
US8313760B2
(en)
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
AU2003241477A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
JP4831965B2
(ja)
*
|
2002-06-10 |
2011-12-07 |
エラン ファーマ インターナショナル,リミティド |
HMG−CoA還元酵素インヒビター誘導体(「スタチン」)を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
|
AU2003261167A1
(en)
|
2002-07-16 |
2004-02-02 |
Elan Pharma International, Ltd |
Liquid dosage compositions of stable nanoparticulate active agents
|
GB0216700D0
(en)
*
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
US20030017208A1
(en)
*
|
2002-07-19 |
2003-01-23 |
Francis Ignatious |
Electrospun pharmaceutical compositions
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
AU2002950426A0
(en)
*
|
2002-07-29 |
2002-09-12 |
Patrick John Shanahan |
Anti microbial oro-dental system
|
US7838034B2
(en)
|
2002-07-30 |
2010-11-23 |
Grunenthal Gmbh |
Intravenous pharmaceutical form of administration
|
DE10234784A1
(de)
*
|
2002-07-30 |
2004-02-19 |
Günenthal GmbH |
Intravenös applizierbare, pharmazeutische Darreichungsform
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040028746A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Sonke Svenson |
Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
|
US20040028747A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Tucker Christopher J. |
Crystalline drug particles prepared using a controlled precipitation process
|
PL375345A1
(en)
|
2002-08-12 |
2005-11-28 |
Pfizer Products Inc. |
Pharmaceutical compositions of semi-ordered drugs and polymers
|
EA010486B1
(ru)
|
2002-08-14 |
2008-10-30 |
Тиботек Фармасьютикалз Лтд. |
Замещенные оксиндолсульфонамидные ингибиторы вич-протеазы широкого спектра действия
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
WO2004035032A2
(en)
*
|
2002-08-20 |
2004-04-29 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
AU2003262911A1
(en)
*
|
2002-08-29 |
2004-03-19 |
Scios Inc. |
Methods of promoting osteogenesis
|
US20060167069A1
(en)
*
|
2002-09-02 |
2006-07-27 |
Sun Pharmaceutical Industries Ltd. |
Pharmaceutical composition of metaxalone with enhanced oral bioavailability
|
PT1553927E
(pt)
*
|
2002-09-11 |
2010-11-22 |
Elan Pharma Int Ltd |
Composições de agentes activos em nanopartículas estabilizadas em gel
|
WO2004053056A2
(en)
*
|
2002-09-24 |
2004-06-24 |
University Of Kentucky Research Foundation |
Nanoparticle-based vaccine delivery system containing adjuvant
|
EP1556091A1
(en)
*
|
2002-10-04 |
2005-07-27 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
US20040105881A1
(en)
*
|
2002-10-11 |
2004-06-03 |
Gregor Cevc |
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
CA2503284A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
WO2004043457A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
ES2365012T3
(es)
*
|
2002-11-12 |
2011-09-20 |
Elan Pharma International Limited |
Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
CA2507484A1
(en)
*
|
2002-11-27 |
2004-06-17 |
Elan Pharmaceuticals, Inc. |
Substituted ureas and carbamates
|
PT1569912E
(pt)
|
2002-12-03 |
2015-09-15 |
Pharmacyclics Llc |
Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
|
US20050095267A1
(en)
*
|
2002-12-04 |
2005-05-05 |
Todd Campbell |
Nanoparticle-based controlled release polymer coatings for medical implants
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
JP2006510654A
(ja)
*
|
2002-12-06 |
2006-03-30 |
サイオス・インコーポレーテツド |
糖尿病を処置する方法
|
CN1310648C
(zh)
*
|
2002-12-13 |
2007-04-18 |
佳高泰克有限公司 |
局部纳米颗粒螺甾内酯制剂
|
US20040173696A1
(en)
*
|
2002-12-17 |
2004-09-09 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
EP1583771B1
(en)
|
2002-12-20 |
2013-04-03 |
Celera Corporation |
Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
GB0230087D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GB0230088D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
MXPA05007266A
(es)
*
|
2003-01-02 |
2006-01-17 |
Femmepharma Holding Co Inc |
Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
|
US9173836B2
(en)
|
2003-01-02 |
2015-11-03 |
FemmeParma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
CN101863930A
(zh)
|
2003-01-06 |
2010-10-20 |
科里克萨有限公司 |
一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
|
CA2513064C
(en)
*
|
2003-01-31 |
2009-11-10 |
Elan Pharma International, Ltd. |
Nanoparticulate topiramate formulations
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
GB0302673D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302671D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302672D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US8512727B2
(en)
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
ATE406364T1
(de)
|
2003-03-07 |
2008-09-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
WO2004081004A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
MXPA05009501A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US20040184995A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel dry powder inhalation for lung-delivery and manufacturing method thereof
|
IE20040202A1
(en)
|
2003-03-28 |
2004-10-06 |
Sigmoid Biotechnologies Ltd |
Solid oral dosage form containing seamless microcapsules
|
US8747908B2
(en)
|
2003-04-09 |
2014-06-10 |
Osmose, Inc. |
Micronized wood preservative formulations
|
US8637089B2
(en)
|
2003-04-09 |
2014-01-28 |
Osmose, Inc. |
Micronized wood preservative formulations
|
NZ542889A
(en)
*
|
2003-04-09 |
2010-02-26 |
Osmose Inc |
Micronized wood preservative formulations comprising dispersions of micronized metal or metal compounds
|
CL2004000848A1
(es)
*
|
2003-04-21 |
2005-01-28 |
Elan Pharmaceuticals Inc Pharm |
Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
|
MXPA05011150A
(es)
*
|
2003-04-21 |
2005-12-14 |
Elan Pharm Inc |
2-hidroxi-3-diaminoalcanos de benzamida.
|
MXPA05012467A
(es)
*
|
2003-05-19 |
2006-02-22 |
Baxter Int |
Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
|
KR20060006086A
(ko)
*
|
2003-05-20 |
2006-01-18 |
로레알 |
2가 산 코폴리머를 이용하여 크기를 안정화시킨 입자
|
FR2855051B1
(fr)
*
|
2003-05-20 |
2006-08-25 |
Oreal |
Particules stabilisees en taille par copolymere diacide
|
DK1631261T3
(da)
*
|
2003-05-22 |
2009-11-09 |
Applied Nanosystems Bv |
Fremstilling af små partikler
|
WO2004105809A1
(en)
*
|
2003-05-22 |
2004-12-09 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
US7459146B2
(en)
*
|
2003-05-30 |
2008-12-02 |
3M Innovative Properties Company |
Stabilized aerosol dispersions
|
US7109247B2
(en)
*
|
2003-05-30 |
2006-09-19 |
3M Innovative Properties Company |
Stabilized particle dispersions containing nanoparticles
|
DE10325989A1
(de)
*
|
2003-06-07 |
2005-01-05 |
Glatt Gmbh |
Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
|
WO2005014650A2
(en)
*
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
NZ544699A
(en)
|
2003-06-17 |
2009-11-27 |
Phibrowood Llc |
Particulate wood preservative and method for producing same
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
WO2004111033A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Astrazeneca Ab |
2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
BRPI0414970A2
(pt)
*
|
2003-06-24 |
2012-12-11 |
Baxter Int |
método para transporte de drogas ao cérebro
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
TWI359675B
(en)
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US8308682B2
(en)
|
2003-07-18 |
2012-11-13 |
Broncus Medical Inc. |
Devices for maintaining patency of surgically created channels in tissue
|
US20050042177A1
(en)
*
|
2003-07-23 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel compositions of sildenafil free base
|
KR20060052849A
(ko)
*
|
2003-08-06 |
2006-05-19 |
에자이 가부시키가이샤 |
약물 초미립자의 제조 방법 및 제조 장치
|
EP1651189B1
(en)
*
|
2003-08-08 |
2008-12-03 |
Elan Pharma International Limited |
Novel metaxalone compositions
|
US7419996B2
(en)
*
|
2003-08-13 |
2008-09-02 |
The University Of Houston |
Parenteral and oral formulations of benzimidazoles
|
GB0319797D0
(en)
*
|
2003-08-26 |
2003-09-24 |
Leuven K U Res & Dev |
Particle size reduction of poorly soluble drugs
|
US20070190129A1
(en)
*
|
2003-09-02 |
2007-08-16 |
Pfizer Inc. |
Sustained release dosage forms of ziprasidone
|
US9149440B2
(en)
*
|
2003-09-02 |
2015-10-06 |
University Of South Florida |
Nanoparticles for drug-delivery
|
TW200518742A
(en)
|
2003-09-11 |
2005-06-16 |
Tibotec Pharm Ltd |
Entry inhibitors
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
PT1663321E
(pt)
|
2003-09-22 |
2012-11-15 |
Baxter Int |
Esterilização a alta pressão para esterilizar definitivamente preparações farmacêuticas e produtos médicos
|
EP1675619A4
(en)
*
|
2003-09-29 |
2010-10-06 |
Palmetto Pharmaceuticals Llc |
EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
CA2542499A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Teva Pharmaceutical Industries Ltd. |
Preparation of candesartan cilexetil
|
US7338171B2
(en)
*
|
2003-10-27 |
2008-03-04 |
Jen-Chuen Hsieh |
Method and apparatus for visual drive control
|
JP2007522079A
(ja)
*
|
2003-10-31 |
2007-08-09 |
エラン ファーマ インターナショナル リミテッド |
ニメスリド組成物
|
ES2366646T3
(es)
*
|
2003-11-05 |
2011-10-24 |
Elan Pharma International Limited |
Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1685085A2
(en)
*
|
2003-11-20 |
2006-08-02 |
Angiotech International Ag |
Implantable sensors and implantable pumps and anti-scarring agents
|
CZ300438B6
(cs)
*
|
2003-11-25 |
2009-05-20 |
Pliva Hrvatska D.O.O. |
Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
|
CA2547072C
(en)
|
2003-11-26 |
2015-06-23 |
Applera Corporation |
Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
|
US20050258288A1
(en)
*
|
2003-11-26 |
2005-11-24 |
E. I. Du Pont De Nemours And Company |
High pressure media milling system and process of forming particles
|
WO2005051511A1
(ja)
*
|
2003-11-28 |
2005-06-09 |
Mitsubishi Chemical Corporation |
有機化合物微粒子の製造方法
|
US9115090B2
(en)
*
|
2003-12-02 |
2015-08-25 |
The Ohio State University Research Foundation |
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
|
KR100603974B1
(ko)
|
2003-12-05 |
2006-07-25 |
김갑식 |
고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
|
ES2584867T3
(es)
*
|
2004-01-12 |
2016-09-29 |
Mannkind Corporation |
Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
|
WO2005070407A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
WO2005072710A2
(en)
*
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
EP1713443A2
(en)
*
|
2004-01-29 |
2006-10-25 |
Baxter International Inc. |
Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
|
US20050169978A1
(en)
*
|
2004-01-29 |
2005-08-04 |
Shu-Wen Fu |
Wet-micro grinding
|
WO2005077941A2
(en)
*
|
2004-02-11 |
2005-08-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
CA2558249A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
US20050239832A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
US20050239836A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20050239790A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
US20080248999A1
(en)
*
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
ATE446581T1
(de)
*
|
2004-03-12 |
2009-11-15 |
Trinity College Dublin |
Magnetoresistives medium
|
US20050202051A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical vehicle
|
US20050203482A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical dispensing apparatus and method
|
RU2006138054A
(ru)
*
|
2004-03-30 |
2008-05-10 |
Смиткайн Бичам Корпорейшн (Us) |
Высушенные распылением фармацевтические композиции
|
JP4875979B2
(ja)
*
|
2004-03-31 |
2012-02-15 |
富山化学工業株式会社 |
難溶性薬物の微粒子分散液およびその製造方法
|
AR048650A1
(es)
|
2004-05-04 |
2006-05-10 |
Tibotec Pharm Ltd |
Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
|
KR100908308B1
(ko)
*
|
2004-05-05 |
2009-07-17 |
테바 파마슈티컬 인더스트리즈 리미티드 |
순도가 높은 칸데사르탄 실렉세틸의 제조
|
WO2005110428A2
(en)
|
2004-05-07 |
2005-11-24 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
EP2412826B1
(en)
|
2004-05-07 |
2014-01-08 |
Celera Corporation |
Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof
|
US7316738B2
(en)
*
|
2004-10-08 |
2008-01-08 |
Phibro-Tech, Inc. |
Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
|
AR052304A1
(es)
|
2004-05-17 |
2007-03-14 |
Tibotec Pharm Ltd |
Compuestos 1,5- dihidro - pirido (3,2-b ) indol-2-onas4- sustituidos, composicion farmaceutica y proceso de preparacion del compuesto
|
BRPI0511175A
(pt)
|
2004-05-17 |
2007-12-04 |
Tibotec Pharm Ltd |
1-hetero-ciclil-1,5-diidro-pirido[3,2-b]indol-2-onas
|
US20050252408A1
(en)
|
2004-05-17 |
2005-11-17 |
Richardson H W |
Particulate wood preservative and method for producing same
|
WO2005111035A1
(en)
|
2004-05-17 |
2005-11-24 |
Tibotec Pharmaceuticals Ltd. |
6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
WO2005115345A1
(en)
*
|
2004-05-28 |
2005-12-08 |
Imaginot Pty Ltd |
Oral therapeutic compound delivery system
|
US8216610B2
(en)
*
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
US8445431B2
(en)
*
|
2004-06-01 |
2013-05-21 |
The Ohio State University |
Ligands having metal binding ability and targeting properties
|
US8012457B2
(en)
|
2004-06-04 |
2011-09-06 |
Acusphere, Inc. |
Ultrasound contrast agent dosage formulation
|
EP1763576A2
(en)
*
|
2004-06-15 |
2007-03-21 |
Baxter International Inc. |
Ex-vivo application of solid microparticulate therapeutic agents
|
WO2006002088A2
(en)
*
|
2004-06-21 |
2006-01-05 |
The Ohio State University Research Foundation |
Amino-quinazoline derivatives as antitumor agents
|
US7385085B2
(en)
*
|
2004-07-09 |
2008-06-10 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
CA2572775A1
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
US8409167B2
(en)
|
2004-07-19 |
2013-04-02 |
Broncus Medical Inc |
Devices for delivering substances through an extra-anatomic opening created in an airway
|
AU2005269800B8
(en)
|
2004-07-19 |
2011-12-01 |
Celator Pharmaceuticals, Inc. |
Particulate constructs for release of active agents
|
EP2218451B1
(en)
*
|
2004-08-18 |
2011-11-30 |
Concordia Pharmaceuticals, Inc. |
Use of FTS for treating malignant disorders
|
EP1791520A2
(en)
*
|
2004-08-19 |
2007-06-06 |
Alza Corporation |
Controlled release nanoparticle active agent formulation dosage forms and methods
|
PL1786784T3
(pl)
|
2004-08-20 |
2011-04-29 |
Mannkind Corp |
Kataliza syntezy diketopiperazyn
|
GB0418791D0
(en)
*
|
2004-08-23 |
2004-09-22 |
Glaxo Group Ltd |
Novel process
|
CN101027057B
(zh)
|
2004-08-23 |
2017-04-12 |
曼金德公司 |
用于药物输送的二酮哌嗪盐、二酮吗啉盐或二酮二氧杂环己烷盐
|
WO2006026533A2
(en)
*
|
2004-08-27 |
2006-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
US9061027B2
(en)
|
2004-08-27 |
2015-06-23 |
Board Of Regents, The University Of Texas System |
Enhanced delivery of drug compositions to treat life threatening infections
|
EP1797934A4
(en)
*
|
2004-09-07 |
2009-09-02 |
Mitsubishi Chem Corp |
METHOD FOR MANUFACTURING FINULY PARTICULATE SUBSTANCE AND FINALLY PARTICULATE SUBSTANCE
|
WO2006034147A2
(en)
*
|
2004-09-16 |
2006-03-30 |
Abraxis Bioscience, Inc. |
Compositions and methods for the preparation and administration of poorly water soluble drugs
|
WO2006035417A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Sigmoid Biotechnologies Limited |
Dihydropyrimidine microcapsule - formulations
|
US7426948B2
(en)
*
|
2004-10-08 |
2008-09-23 |
Phibrowood, Llc |
Milled submicron organic biocides with narrow particle size distribution, and uses thereof
|
AU2005296077B2
(en)
*
|
2004-10-14 |
2010-12-23 |
Koppers Performance Chemicals Inc. |
Micronized wood preservative formulations in organic carriers
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
US20080095722A1
(en)
*
|
2004-11-12 |
2008-04-24 |
Idea Ag |
Extended Surface Aggregates in the Treatment of Skin Conditions
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
EP1827374B1
(en)
*
|
2004-11-16 |
2014-11-05 |
Alkermes Pharma Ireland Limited |
Injectable nanoparticulate olanzapine formulations
|
WO2006121468A1
(en)
*
|
2004-11-22 |
2006-11-16 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
JPWO2006062238A1
(ja)
*
|
2004-12-07 |
2008-06-12 |
味の素株式会社 |
アミノ酸の微粉末及びその懸濁液
|
WO2006062875A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Merck & Co., Inc. |
Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
|
EP1835889A1
(en)
*
|
2004-12-15 |
2007-09-26 |
Elan Pharma International Limited |
Nanoparticulate tacrolimus formulations
|
EP1837015A1
(en)
*
|
2004-12-17 |
2007-09-26 |
Mitsubishi Chemical Corporation |
Novel core-shell structure
|
US20060159767A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Elan Pharma International Limited |
Nanoparticulate bicalutamide formulations
|
AU2012201630B8
(en)
*
|
2004-12-31 |
2014-03-06 |
Iceutica Pty Ltd |
NanoParticle Composition(s) and Method for Synthesis Thereof
|
CA2858733C
(en)
*
|
2004-12-31 |
2017-12-19 |
Iceutica Pty Ltd |
Nanoparticle compositions and methods for synthesis thereof
|
AU2005321751B2
(en)
*
|
2004-12-31 |
2012-04-05 |
Iceutica Pty Ltd |
Nanoparticle composition and methods for synthesis thereof
|
BRPI0606434A2
(pt)
*
|
2005-01-06 |
2009-06-30 |
Elan Pharma Int Ltd |
formulações de candesartana nanoparticulada
|
US20080145431A1
(en)
*
|
2005-01-07 |
2008-06-19 |
Teruko Nomura |
Medicinal Composition and Process for Producing the Same
|
JP5288791B2
(ja)
*
|
2005-01-28 |
2013-09-11 |
武田薬品工業株式会社 |
難水溶性物質含有微細化組成物
|
ES2265262B1
(es)
*
|
2005-01-31 |
2008-03-01 |
Activery Biotech, S.L.(Titular Al 50%) |
Procedimiento para la obtencion de sistemas micro- y nanodispersos.
|
US7507794B2
(en)
|
2005-02-08 |
2009-03-24 |
Research Development Foundation |
Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2)
|
US20060198896A1
(en)
*
|
2005-02-15 |
2006-09-07 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
AR058419A1
(es)
*
|
2005-02-28 |
2008-02-06 |
Gilead Sciences Inc |
Compuestos de nucleosidos triciclicos para tratar infecciones virales
|
AU2005100176A4
(en)
*
|
2005-03-01 |
2005-04-07 |
Gym Tv Pty Ltd |
Garbage bin clip
|
EP1855651A4
(en)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
|
WO2006099121A2
(en)
*
|
2005-03-10 |
2006-09-21 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
|
EP2113572B1
(en)
|
2005-03-11 |
2012-12-05 |
Celera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
WO2006099591A1
(en)
*
|
2005-03-16 |
2006-09-21 |
Elan Pharma International Limited |
Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
|
NZ561666A
(en)
*
|
2005-03-17 |
2010-05-28 |
Elan Pharma Int Ltd |
Nanoparticulate biphosphonate compositions
|
EA200702049A1
(ru)
*
|
2005-03-23 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
Композиции наночастиц кортикостероидов с антигистаминами
|
US20070224282A1
(en)
*
|
2005-03-28 |
2007-09-27 |
Toyama Chemical Co., Ltd. |
Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
|
EA201001322A1
(ru)
|
2005-03-31 |
2011-02-28 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцины против хламидиоза
|
TW200710091A
(en)
|
2005-04-11 |
2007-03-16 |
Tibotec Pharm Ltd |
(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
|
JP2008535921A
(ja)
*
|
2005-04-12 |
2008-09-04 |
エラン・ファルマ・インターナショナル・リミテッド |
シクロスポリンを含むナノ粒子および放出調節された組成物
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
WO2006110811A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
AU2006233345A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Pfizer Products Inc. |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
EP1868574B1
(de)
*
|
2005-04-13 |
2010-01-06 |
Abbott GmbH & Co. KG |
Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
|
US20090252807A1
(en)
*
|
2005-04-13 |
2009-10-08 |
Elan Pharma International Limited |
Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
TW200720285A
(en)
*
|
2005-04-25 |
2007-06-01 |
Genelabs Tech Inc |
Nucleoside compounds for treating viral infections
|
PT2457926E
(pt)
|
2005-04-29 |
2014-11-25 |
Glaxosmithkline Biolog Sa |
Método para prevenção ou tratamento de uma infecção por m. tuberculosis
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
AU2006336417A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International, Limited |
Nanoparticulate clopidogrel formulations
|
US20110064803A1
(en)
*
|
2005-05-10 |
2011-03-17 |
Elan Pharma International Limited. |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
KR100978592B1
(ko)
*
|
2005-05-10 |
2010-08-27 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
|
JP2008540550A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン・ファルマ・インターナショナル・リミテッド |
ビタミンk2を含むナノ粒子および制御放出組成物
|
EP1915139A1
(en)
*
|
2005-05-16 |
2008-04-30 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
CA2611506A1
(en)
*
|
2005-05-23 |
2006-11-23 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
|
US20060275372A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Elan Pharma International Limited |
Nanoparticulate imatinib mesylate formulations
|
US20070042049A1
(en)
*
|
2005-06-03 |
2007-02-22 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
KR20080017065A
(ko)
*
|
2005-06-03 |
2008-02-25 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 아세트아미노펜 제제
|
ES2400772T3
(es)
*
|
2005-06-07 |
2013-04-12 |
Ramot At Tel Aviv University Ltd. |
Sales novedosas de fármacos psicotrópicos conjugados y procedimientos para la preparación de las mismas
|
CA2612994A1
(en)
|
2005-06-08 |
2006-12-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cefditoren
|
CA2611475A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Elan Pharma International, Limited |
Nanoparticulate ebastine formulations
|
KR20080016952A
(ko)
*
|
2005-06-13 |
2008-02-22 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 클로피도그렐과 아스피린의 배합 제제
|
CA2612384A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Elan Pharma International, Limited |
Nanoparticulate azelnidipine formulations
|
AU2006285349A1
(en)
*
|
2005-06-20 |
2007-03-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
|
KR20080024213A
(ko)
*
|
2005-06-22 |
2008-03-17 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 메게스트롤 제제
|
BRPI0612124A2
(pt)
*
|
2005-06-24 |
2010-10-19 |
Genelabs Tech Inc |
derivados de heteroarila para o tratamento de viroses
|
US8951560B2
(en)
*
|
2005-06-29 |
2015-02-10 |
Dsm Ip Assets B.V. |
Isoflavone nanoparticles and use thereof
|
WO2007000842A1
(ja)
*
|
2005-06-29 |
2007-01-04 |
Mitsubishi Chemical Corporation |
粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
|
CA2614409C
(en)
*
|
2005-07-07 |
2014-05-20 |
Nanotherapeutics, Inc |
Process for milling and preparing powders and compositions produced thereby
|
EP1904041A2
(en)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
US20070298109A1
(en)
*
|
2005-07-07 |
2007-12-27 |
The Trustees Of The University Of Pennsylvania |
Nano-scale devices
|
CA2615378C
(en)
*
|
2005-07-15 |
2015-02-17 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
EP1915134A2
(en)
*
|
2005-08-10 |
2008-04-30 |
Novartis AG |
Formulations for 7-(t-butoxy)iminomethyl camptothecin
|
CN101287448A
(zh)
*
|
2005-08-10 |
2008-10-15 |
诺瓦提斯公司 |
拓扑异构酶i的抑制剂7-叔丁氧基亚氨基甲基喜树碱的微粒组合物
|
GB0516549D0
(en)
*
|
2005-08-12 |
2005-09-21 |
Sulaiman Brian |
Milling system
|
MX2008001919A
(es)
*
|
2005-08-12 |
2008-03-24 |
Astrazeneca Ab |
Proceso para la preparacion de una dispersion estable de particulas submicronicas en un medio acuoso.
|
HUE042678T2
(hu)
|
2005-08-31 |
2019-07-29 |
Abraxis Bioscience Llc |
Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
|
NZ592132A
(en)
*
|
2005-08-31 |
2012-12-21 |
Abraxis Bioscience Llc |
Composition comprising nanoparticles of docitaxel and a citrate
|
EP1923051A4
(en)
*
|
2005-09-06 |
2012-12-19 |
Astellas Pharma Inc |
MICROPARTICLES OF A HEAVY-DUTY SUBSTANCE WITH ENTERIAN BASE MATERIAL ADSORBED ON THE SUBSTANCE SURFACE
|
JP2009507925A
(ja)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子タダラフィル製剤
|
EP1928423B1
(en)
|
2005-09-14 |
2015-12-09 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
|
WO2007035348A2
(en)
*
|
2005-09-15 |
2007-03-29 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US7713929B2
(en)
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US20070086952A1
(en)
*
|
2005-09-29 |
2007-04-19 |
Biodel, Inc. |
Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
|
WO2007041079A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Alza Corporation |
Banded controlled release nanoparticle active agent formulation dosage forms and methods
|
EA019255B1
(ru)
|
2005-10-07 |
2014-02-28 |
Экселиксис, Инк. |
Ингибиторы фосфатидилинозит-3-киназы и содержащие их фармацевтические композиции
|
GEP20115304B
(en)
|
2005-10-07 |
2011-10-10 |
Exelixis Inc |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
|
JP2009511589A
(ja)
*
|
2005-10-12 |
2009-03-19 |
エラン ファーマシューティカルズ,インコーポレイテッド |
アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
US7695911B2
(en)
|
2005-10-26 |
2010-04-13 |
Celera Corporation |
Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
|
DE102005053862A1
(de)
*
|
2005-11-04 |
2007-05-10 |
Pharmasol Gmbh |
Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
JP2009517346A
(ja)
*
|
2005-11-28 |
2009-04-30 |
イメイジノット ピーティーワイ エルティーディー |
治療用化合物の経口送達系
|
NZ568700A
(en)
*
|
2005-11-28 |
2012-03-30 |
Marinus Pharmaceuticals |
Solid stabilized particulate formulations comprising ganaxolone
|
US20120121653A1
(en)
*
|
2005-12-02 |
2012-05-17 |
Elan Pharma International Limited |
Novel mometasone compositions and methods of making and using the same
|
TW200730478A
(en)
*
|
2005-12-12 |
2007-08-16 |
Genelabs Tech Inc |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
WO2007089335A2
(en)
|
2005-12-29 |
2007-08-09 |
Lexicon Pharmaceutical Inc. |
Multicyclic amino acid derivatives and methods of their use
|
CA2636424A1
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
|
JP2009526860A
(ja)
*
|
2006-02-15 |
2009-07-23 |
ティカ レーケメデル アーベー |
安定したコルチコステロイド混合物
|
ES2647080T3
(es)
|
2006-02-22 |
2017-12-19 |
Mannkind Corporation |
Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
|
WO2007095716A1
(en)
*
|
2006-02-23 |
2007-08-30 |
Iomedix Sleep International Srl |
Compositions and methods for the induction and maintenance of quality sleep
|
US7649098B2
(en)
|
2006-02-24 |
2010-01-19 |
Lexicon Pharmaceuticals, Inc. |
Imidazole-based compounds, compositions comprising them and methods of their use
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20090099175A1
(en)
*
|
2006-03-01 |
2009-04-16 |
Arrington Mark P |
Phosphodiesterase 10 inhibitors
|
US11311477B2
(en)
|
2006-03-07 |
2022-04-26 |
Sgn Nanopharma Inc. |
Ophthalmic preparations
|
US10137083B2
(en)
|
2006-03-07 |
2018-11-27 |
SGN Nanopharma Inc |
Ophthalmic preparations
|
AU2007224006A1
(en)
*
|
2006-03-07 |
2007-09-13 |
Novavax, Inc. |
Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
|
CN102631323A
(zh)
*
|
2006-03-14 |
2012-08-15 |
默克公司 |
通过微研磨和在微晶种上结晶生产结晶有机微粒组合物的方法和设备及其应用
|
MX2008012790A
(es)
|
2006-04-03 |
2008-10-15 |
Tibotec Pharm Ltd |
3,4-dihidro-imidazo[4,5-b]piridin-5-onas inhibidoras de virus de inmunodeficiencia humana.
|
WO2007121256A2
(en)
*
|
2006-04-12 |
2007-10-25 |
Biodel, Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2008054508A2
(en)
*
|
2006-04-13 |
2008-05-08 |
Alza Corporation |
Stable nanosized amorphous drug
|
LT2010528T
(lt)
|
2006-04-19 |
2017-12-27 |
Novartis Ag |
6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
|
JP2007306950A
(ja)
|
2006-05-15 |
2007-11-29 |
Osaka Univ |
薬効成分ナノ粒子分散液の製造方法
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
JP2009538927A
(ja)
*
|
2006-05-30 |
2009-11-12 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子状のポサコナゾール製剤
|
JP5406022B2
(ja)
*
|
2006-06-12 |
2014-02-05 |
スミス アンド ネフュー インコーポレーテッド |
脛骨切除システム、方法、及び装置
|
MX2008015764A
(es)
*
|
2006-06-14 |
2009-01-07 |
Intervet Int Bv |
Suspension que comprende carbamato de bencimidazol y polisorbato.
|
WO2008002485A2
(en)
*
|
2006-06-23 |
2008-01-03 |
Alza Corporation |
Increased amorphous stability of poorly water soluble drugs by nanosizing
|
PL2040671T3
(pl)
|
2006-06-23 |
2018-08-31 |
Janssen Sciences Ireland Uc |
Wodne zawiesiny TMC278
|
MX2009000035A
(es)
*
|
2006-06-26 |
2009-05-28 |
Mutual Pharmaceutical Co |
Formulaciones de agente activo, procedimientos de preparacion y procedimientos de uso.
|
US7538114B2
(en)
|
2006-06-28 |
2009-05-26 |
Amgen Inc. |
Glycine transporter-1 inhibitors
|
IN2014MN00380A
(zh)
*
|
2006-06-30 |
2015-06-19 |
Iceutica Pty Ltd |
|
US8808751B2
(en)
*
|
2006-06-30 |
2014-08-19 |
Iceutica Pty Ltd. |
Methods for the preparation of biologically active compounds in nanoparticulate form
|
JP2009543797A
(ja)
*
|
2006-07-10 |
2009-12-10 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子ソラフェニブ製剤
|
KR20090048462A
(ko)
*
|
2006-07-17 |
2009-05-13 |
라모트 앳 텔-아비브 유니버시티 리미티드 |
통증완화용 gaba 접합체
|
BRPI0714299A2
(pt)
*
|
2006-07-20 |
2013-04-24 |
Genelabs Tech Inc |
inibidores virais policÍclicos
|
US20100003332A1
(en)
*
|
2006-07-27 |
2010-01-07 |
Amorepacific Corporation |
Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
|
EP2054397B1
(en)
|
2006-08-16 |
2015-10-07 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Small molecule inhibitors of kynurenine-3-monooxygenase
|
WO2008022286A2
(en)
*
|
2006-08-16 |
2008-02-21 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Small molecule inhibitors of kynurenine-3-monooxygenase
|
WO2008026216A2
(en)
*
|
2006-08-28 |
2008-03-06 |
Hetero Drugs Limited |
Process for purification of aprepitant
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
ATE498393T1
(de)
*
|
2006-09-08 |
2011-03-15 |
Univ Johns Hopkins |
Zusammensetzungen zur transportintensivierung durch die schleimhaut
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
WO2008085556A2
(en)
|
2006-09-12 |
2008-07-17 |
University Of South Florida |
Surfactant-free nanoparticles for drug delivery
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8084443B2
(en)
|
2007-10-01 |
2011-12-27 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US9598462B2
(en)
|
2012-01-26 |
2017-03-21 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
WO2008032327A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
AR063704A1
(es)
*
|
2006-09-14 |
2009-02-11 |
Makhteshim Chem Works Ltd |
Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
AU2007298674A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Labopharm (Barbados) Limited |
Compositions and methods for pH targeted drug delivery
|
CN1946120B
(zh)
*
|
2006-10-20 |
2010-05-12 |
华为技术有限公司 |
实现话单关联的方法及系统
|
WO2008051511A2
(en)
|
2006-10-20 |
2008-05-02 |
Applera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
US8946200B2
(en)
*
|
2006-11-02 |
2015-02-03 |
Southwest Research Institute |
Pharmaceutically active nanosuspensions
|
WO2008061013A2
(en)
*
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
EP2094731A2
(en)
*
|
2006-11-10 |
2009-09-02 |
UCB Pharma S.A. |
Anti human sclerostin antibodies
|
CA2669392C
(en)
*
|
2006-11-17 |
2016-05-10 |
Abbott Gmbh & Co. Kg |
Nanocrystals for use in topical cosmetic formulations and method of production thereof
|
KR20080047956A
(ko)
*
|
2006-11-27 |
2008-05-30 |
주식회사 엠디바이오알파 |
발기부전의 치료 및 예방을 위한 약제 조성물
|
JP2010510988A
(ja)
*
|
2006-11-28 |
2010-04-08 |
マリナス ファーマシューティカルズ |
ナノ粒子製剤とその製造方法およびその利用
|
US20090028935A1
(en)
*
|
2006-12-01 |
2009-01-29 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20080292695A1
(en)
*
|
2006-12-01 |
2008-11-27 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
EP1938800A1
(en)
|
2006-12-06 |
2008-07-02 |
Ranbaxy Laboratories Limited |
Sirolimus nanodispersion
|
UA99270C2
(en)
|
2006-12-12 |
2012-08-10 |
Лексикон Фармасьютикалз, Инк. |
4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
|
US20080153789A1
(en)
*
|
2006-12-26 |
2008-06-26 |
Femmepharma Holding Company, Inc. |
Topical administration of danazol
|
DE102007001473A1
(de)
|
2007-01-08 |
2008-07-10 |
Andreas Lemke |
Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
|
US20100068287A1
(en)
*
|
2007-02-09 |
2010-03-18 |
Astrazeneca Ab |
Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium
|
TW200848039A
(en)
*
|
2007-02-09 |
2008-12-16 |
Astrazeneca Ab |
Pharmaceutical compositions
|
HUE026884T2
(en)
|
2007-02-11 |
2016-08-29 |
Map Pharmaceuticals Inc |
DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
|
EP2134327A1
(en)
*
|
2007-03-13 |
2009-12-23 |
Sandoz AG |
Pharmaceutical compositions of poorly soluble drugs
|
EP2134695A4
(en)
|
2007-03-14 |
2011-05-25 |
Exelixis Inc |
HEMGE OF THE HEDGEHOG SIGNAL PATH
|
CL2008000746A1
(es)
|
2007-03-14 |
2008-09-22 |
Tibotec Pharm Ltd |
Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
|
WO2008122967A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Sigmoid Pharma Limited |
An oral pharmaceutical composition
|
TWI405590B
(zh)
|
2007-04-06 |
2013-08-21 |
Activus Pharma Co Ltd |
微粉碎化有機化合物粒子之製法
|
WO2008124724A1
(en)
|
2007-04-09 |
2008-10-16 |
University Of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
EP2061587A1
(en)
|
2007-04-26 |
2009-05-27 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
CA2685591A1
(en)
*
|
2007-05-01 |
2008-11-06 |
Sigmoid Pharma Limited |
Pharmaceutical nimodipine compositions
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
US8530463B2
(en)
*
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
EP2152274A4
(en)
*
|
2007-05-07 |
2010-07-21 |
Questor Pharmaceuticals Inc |
NASAL ADMINISTRATION OF BENZODIAZEPINES
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US7883995B2
(en)
*
|
2007-05-31 |
2011-02-08 |
The Administrators Of The Tulane Educational Fund |
Method of forming stable functionalized nanoparticles
|
WO2008149192A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
JP4419157B2
(ja)
|
2007-07-06 |
2010-02-24 |
エム・テクニック株式会社 |
生体摂取物微粒子の製造方法
|
RU2498979C2
(ru)
|
2007-07-12 |
2013-11-20 |
Тиботек Фармасьютикалз |
Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
|
ATE554751T1
(de)
|
2007-07-13 |
2012-05-15 |
Bend Res Inc |
Nanopartikel mit einem nicht ionisierbaren polymer und einem anionischen zellulosepolymer
|
US20090176778A1
(en)
*
|
2007-08-10 |
2009-07-09 |
Franz Ulrich Schmitz |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
RU2468034C2
(ru)
|
2007-08-27 |
2012-11-27 |
ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи |
Иммуногенные композиции и способы
|
WO2009029729A1
(en)
*
|
2007-08-31 |
2009-03-05 |
Genelabs Technologies, Inc. |
Amino tricyclic-nucleoside compounds, compositions, and methods of use
|
KR101545874B1
(ko)
*
|
2007-09-03 |
2015-08-20 |
나노테라퓨틱스, 인코포레이티드 |
난용성 약물의 전달을 위한 입상 조성물
|
US20090068266A1
(en)
*
|
2007-09-11 |
2009-03-12 |
Raheja Praveen |
Sirolimus having specific particle size and pharmaceutical compositions thereof
|
US20090130210A1
(en)
*
|
2007-09-11 |
2009-05-21 |
Raheja Praveen |
Pharmaceutical compositions of sirolimus
|
US8232413B2
(en)
*
|
2007-09-12 |
2012-07-31 |
Merck Sharp & Dohme Corp. |
Process for the production of a crystalline glucagon receptor antagonist compound
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
DK2200588T3
(da)
|
2007-09-25 |
2019-07-01 |
Solubest Ltd |
Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US20100209513A1
(en)
*
|
2007-10-11 |
2010-08-19 |
In Geun Jo |
Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
|
WO2009049304A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Map Pharmaceuticals, Inc. |
Inhalation drug delivery
|
US9206233B2
(en)
|
2007-10-19 |
2015-12-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Templates for controlling synthesis of nanoparticles into discrete assemblies
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
JP2011503232A
(ja)
|
2007-11-20 |
2011-01-27 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
免疫応答の調節
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
JP5745855B2
(ja)
|
2007-11-28 |
2015-07-08 |
セコイア、ファーマシューティカルズ、インコーポレイテッドSequoia Pharmaceuticals,Inc. |
シトクロムp450 2d6を阻害するための組成物および方法
|
US9724362B2
(en)
|
2007-12-06 |
2017-08-08 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
WO2009073216A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
|
KR100961880B1
(ko)
*
|
2007-12-12 |
2010-06-09 |
중앙대학교 산학협력단 |
밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
EP2227256A1
(en)
*
|
2007-12-14 |
2010-09-15 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
US8940771B2
(en)
|
2007-12-20 |
2015-01-27 |
Novartis Ag |
Organic compounds
|
US9242295B2
(en)
|
2007-12-21 |
2016-01-26 |
The Univeristy Of Texas At Arlington |
Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
|
US20090197856A1
(en)
*
|
2007-12-21 |
2009-08-06 |
Genelabs Technologies, Inc. |
Antiviral compounds
|
US20100054981A1
(en)
|
2007-12-21 |
2010-03-04 |
Board Of Regents, The University Of Texas System |
Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
|
KR101405823B1
(ko)
*
|
2007-12-24 |
2014-06-12 |
주식회사 케이티앤지생명과학 |
녹내장의 치료 및 예방을 위한 약제 조성물
|
KR20090071829A
(ko)
*
|
2007-12-28 |
2009-07-02 |
주식회사 머젠스 |
신장질환의 치료 및 예방을 위한 약제 조성물
|
WO2009089181A1
(en)
*
|
2008-01-04 |
2009-07-16 |
Blodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
IL188647A0
(en)
*
|
2008-01-08 |
2008-11-03 |
Orina Gribova |
Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
|
US20090202649A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Subhash Gore |
Fenofibrate formulations
|
EP2252578B1
(en)
|
2008-02-11 |
2012-08-01 |
Ramot at Tel Aviv University Ltd. |
Conjugates for treating neurodegenerative diseases and disorders
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
US8906647B2
(en)
|
2008-02-21 |
2014-12-09 |
Sequoia Pharmaceuticals, Inc. |
Diamide inhibitors of cytochrome P450
|
EP2254555A4
(en)
*
|
2008-02-27 |
2013-10-09 |
Reddys Lab Ltd Dr |
APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
|
US9364443B2
(en)
|
2008-03-05 |
2016-06-14 |
Baxter International, Inc. |
Compositions and methods for drug delivery
|
US8404850B2
(en)
*
|
2008-03-13 |
2013-03-26 |
Southwest Research Institute |
Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
|
JP2011520779A
(ja)
*
|
2008-03-21 |
2011-07-21 |
エラン・ファルマ・インターナショナル・リミテッド |
イマチニブの部位特異的送達のための組成物および使用の方法
|
ES2586032T3
(es)
|
2008-03-28 |
2016-10-11 |
Hale Biopharma Ventures, Llc |
Administración de composiciones de benzodiazepinas
|
HU230862B1
(hu)
*
|
2008-04-28 |
2018-10-29 |
DARHOLDING Vagyonkezelő Kft |
Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
|
WO2009140341A2
(en)
*
|
2008-05-13 |
2009-11-19 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin compositions
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
EP2567723B1
(en)
|
2008-06-13 |
2021-01-20 |
MannKind Corporation |
A dry powder inhaler and system for drug delivery
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
ES2421385T3
(es)
|
2008-06-20 |
2013-09-02 |
Mannkind Corp |
Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
|
WO2010006215A1
(en)
|
2008-07-09 |
2010-01-14 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
|
US20100151037A1
(en)
*
|
2008-08-07 |
2010-06-17 |
Yivan Jiang |
Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
|
DE102008037025C5
(de)
*
|
2008-08-08 |
2016-07-07 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
|
TWI532497B
(zh)
|
2008-08-11 |
2016-05-11 |
曼凱公司 |
超快起作用胰島素之用途
|
US8722706B2
(en)
*
|
2008-08-15 |
2014-05-13 |
Southwest Research Institute |
Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
|
AU2009282888C1
(en)
|
2008-08-19 |
2014-01-23 |
Xenoport, Inc. |
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
|
US9700525B2
(en)
|
2008-08-20 |
2017-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College |
Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
|
BRPI0918142A2
(pt)
|
2008-09-10 |
2015-12-01 |
Biochemics Inc |
composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
|
PT2345426E
(pt)
*
|
2008-09-19 |
2014-06-09 |
Activus Pharma Co Ltd |
Composto orgânico compósito em pó para utilização médica, método de produção do mesmo e suspensão do mesmo
|
TWI580441B
(zh)
*
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
GB0818403D0
(en)
*
|
2008-10-08 |
2008-11-12 |
Univ Leuven Kath |
Aqueous electrophoretic deposition
|
US8309134B2
(en)
*
|
2008-10-03 |
2012-11-13 |
Southwest Research Institute |
Modified calcium phosphate nanoparticle formation
|
WO2010040648A2
(en)
*
|
2008-10-06 |
2010-04-15 |
Katholieke Universiteit Leuven, K.U.Leuven R&D |
Functional layers of biomolecules and living cells, and a novel system to produce such
|
US20100098770A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Manikandan Ramalingam |
Sirolimus pharmaceutical formulations
|
US8277697B2
(en)
*
|
2008-10-29 |
2012-10-02 |
Global Oled Technology Llc |
Color filter element with improved colorant dispersion
|
US20100160369A1
(en)
|
2008-12-04 |
2010-06-24 |
Exelixis, Inc. |
S1P1 Agonists and Methods of Making And Using
|
JP5723287B2
(ja)
|
2008-12-15 |
2015-05-27 |
バナー ライフ サイエンシズ エルエルシー |
非水溶性活性薬剤の放出および吸収を増強するための方法
|
AU2009333214B2
(en)
|
2008-12-17 |
2013-09-26 |
Amgen Inc. |
Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
CN102341103A
(zh)
|
2009-01-02 |
2012-02-01 |
爱尔兰福尼雅实验室有限公司 |
贝特类的新用途
|
WO2010080754A2
(en)
|
2009-01-06 |
2010-07-15 |
Pharmanova, Inc. |
Nanoparticle pharmaceutical formulations
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
US20100183687A1
(en)
*
|
2009-01-22 |
2010-07-22 |
Cox D Phillip |
Process for preparing particles of opioids and compositions produced thereby
|
AR075180A1
(es)
*
|
2009-01-29 |
2011-03-16 |
Novartis Ag |
Formulaciones orales solidas de una pirido-pirimidinona
|
WO2010087447A1
(ja)
|
2009-01-30 |
2010-08-05 |
明治製菓株式会社 |
微粉砕医薬組成物
|
CN104523661A
(zh)
*
|
2009-02-06 |
2015-04-22 |
南加利福尼亚大学 |
含有单萜的治疗组合物
|
WO2010091164A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Inhibitors of glucosylceramide synthase
|
WO2010091104A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Glucosylceramide synthase inhibitors
|
US20100204265A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
EP2398791A1
(en)
|
2009-02-18 |
2011-12-28 |
Amgen, Inc |
INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
|
JP5809985B2
(ja)
|
2009-02-26 |
2015-11-11 |
グラクソ グループ リミテッドGlaxo Group Limited |
4−{(1r)−2−[(6−{2−[(2,6−ジクロロベンジル)オキシ]エトキシ}ヘキシル)アミノ]−1−ヒドロキシエチル}−2−(ヒドロキシメチル)フェノールを含む医薬製剤
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
EP2676695A3
(en)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
EP2411039A4
(en)
|
2009-03-23 |
2015-05-06 |
Brigham & Womens Hospital |
Glycoconjugate VACCINES
|
US7828996B1
(en)
*
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010117662A1
(en)
|
2009-03-30 |
2010-10-14 |
Exelixis, Inc. |
Modulators of s1p and methods of making and using
|
KR20120022895A
(ko)
*
|
2009-04-09 |
2012-03-12 |
엘커메스 파마 아일랜드 리미티드 |
약물 전달 조성물
|
US20100268187A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Ranbaxy Laboratories Limited |
Packaging for sirolimus and composition thereof
|
EP2421513B1
(en)
|
2009-04-24 |
2017-12-13 |
Iceutica Pty Ltd. |
A novel formulation of indomethacin
|
AP3774A
(en)
|
2009-04-24 |
2016-08-31 |
Iceutica Pty Ltd |
A novel formulation of diclofenac
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
US10952965B2
(en)
*
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
EP2253306A1
(en)
|
2009-05-18 |
2010-11-24 |
Royal College of Surgeons in Ireland |
Orodispersible dosage forms containing solid drug dispersions
|
JP5640079B2
(ja)
|
2009-05-18 |
2014-12-10 |
シグモイド・ファーマ・リミテッドSigmoid Pharma Limited |
油滴含有組成物
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
JP6072539B2
(ja)
|
2009-05-27 |
2017-02-01 |
アルカーメス ファーマ アイルランド リミテッド |
ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
TR200904500A2
(tr)
|
2009-06-10 |
2009-10-21 |
Öner Levent |
Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
|
KR20210027546A
(ko)
|
2009-06-12 |
2021-03-10 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
US9044475B2
(en)
|
2009-06-12 |
2015-06-02 |
Cynapsus Therapeutics, Inc. |
Sublingual apomorphine
|
JP5775071B2
(ja)
|
2009-06-16 |
2015-09-09 |
ファイザー・インク |
アピキサバンの製剤形
|
US9149024B2
(en)
|
2009-06-22 |
2015-10-06 |
Massachusetts Eye & Ear Infirmary |
Islet1 (Isl1) and hearing loss
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US20110003000A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Femmepharma Holding Company, Inc. |
Transvaginal Delivery of Drugs
|
AU2010269815B2
(en)
|
2009-07-09 |
2015-10-15 |
Oshadi Drug Administration Ltd. |
Matrix carrier compositions, methods and uses
|
WO2011006066A1
(en)
|
2009-07-10 |
2011-01-13 |
Ironwood Pharmaceuticals, Inc. |
Cb receptor agonists
|
EP2283824B1
(en)
|
2009-07-30 |
2017-04-19 |
Special Products Line S.p.A. |
Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011018504A2
(en)
|
2009-08-12 |
2011-02-17 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
EP2298296A1
(en)
|
2009-08-25 |
2011-03-23 |
CNRS Centre National De La Recherche Scientifique |
Composition and method for treating cognitive impairments in down syndrome subjects
|
EP2470560B1
(en)
|
2009-08-28 |
2015-06-10 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
US9775819B2
(en)
*
|
2009-09-16 |
2017-10-03 |
R.P. Scherer Technologies, Llc |
Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
RU2481100C2
(ru)
*
|
2009-10-16 |
2013-05-10 |
Лайфкеа Инновейшнз Пвт. Лтд. |
Новая лекарственная форма для лечения грибковой инфекции
|
CA2778441C
(en)
|
2009-10-22 |
2019-01-08 |
Api Genesis, Llc |
Hydrated microparticles of apigenin and/or luteolin with improved solubility
|
CA2778698A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
EP2496231A1
(en)
|
2009-11-05 |
2012-09-12 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for the treatment of cancer
|
MX337893B
(es)
*
|
2009-11-10 |
2016-03-28 |
Celgene Corp |
Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion.
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
HUE025838T2
(en)
|
2009-12-03 |
2016-04-28 |
Alcon Res Ltd |
Nanoparticulate suspensions containing carboxyvinyl polymer
|
WO2011070579A1
(en)
*
|
2009-12-09 |
2011-06-16 |
Biolinerx Ltd. |
Methods of improving cognitive functions
|
CN102781922A
(zh)
|
2009-12-11 |
2012-11-14 |
埃克塞利希斯股份有限公司 |
Tgr5激动剂
|
WO2011075636A2
(en)
|
2009-12-18 |
2011-06-23 |
Amgen Inc. |
Wise binding agents and epitopes
|
BR112012015449B1
(pt)
|
2009-12-22 |
2021-09-28 |
Leo Pharma A/S |
Suspensão de monoidrato de calcipotriol, e, processo para preparar nanocristais de monoidrato de calcipotriol
|
US8674115B2
(en)
|
2009-12-23 |
2014-03-18 |
Ironwood Pharmaceuticals, Inc. |
CRTH2 modulators
|
SG182573A1
(en)
|
2010-01-27 |
2012-08-30 |
Glaxosmithkline Biolog Sa |
Modified tuberculosis antigens
|
US9028873B2
(en)
*
|
2010-02-08 |
2015-05-12 |
Southwest Research Institute |
Nanoparticles for drug delivery to the central nervous system
|
WO2011100324A1
(en)
|
2010-02-09 |
2011-08-18 |
Ironwood Pharmaceuticals Inc. |
Cannabinoid receptor agonists
|
US20130178453A1
(en)
|
2010-02-09 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Agonists
|
US8901137B2
(en)
|
2010-02-09 |
2014-12-02 |
Exelixis, Inc. |
Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
|
CA2789229A1
(en)
|
2010-02-10 |
2011-08-18 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
|
MX2012009561A
(es)
|
2010-02-17 |
2012-11-23 |
Amgen Inc |
Carboxamidas como inhibidores de canales de sodio dependientes del voltaje.
|
EP2539337A1
(en)
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
AU2011219529A1
(en)
*
|
2010-02-24 |
2012-08-30 |
Bar-Ilan University |
Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same
|
US9168504B2
(en)
*
|
2010-03-11 |
2015-10-27 |
Hamamatsu Photonics K.K. |
Fine-particle dispersion liquid manufacturing method and fine-particle dispersion liquid manufacturing apparatus
|
EP2551237B1
(en)
|
2010-03-22 |
2024-09-04 |
Bio-Synectics Inc. |
Method for preparing nano-particles
|
SI2609923T1
(sl)
|
2010-03-31 |
2017-10-30 |
Gilead Pharmasset Llc |
Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
DE102010003711B4
(de)
*
|
2010-04-08 |
2015-04-09 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoffpartikel
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
EP2561067B1
(en)
|
2010-04-23 |
2018-11-14 |
University of Florida Research Foundation, Inc. |
Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
|
US9101541B2
(en)
|
2010-04-28 |
2015-08-11 |
Cadila Healthcare Limited |
Stable solid pharmaceutical matrix compositions of sirolimus
|
EP2566461A2
(de)
*
|
2010-05-05 |
2013-03-13 |
Ratiopharm GmbH |
Festes tapentadol in nicht-kristalliner form
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
AU2011253058A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
|
AU2011253057B2
(en)
|
2010-05-13 |
2014-11-20 |
Amgen Inc. |
Nitrogen heterocyclic compounds useful as PDE10 inhibitors
|
EP2569299A1
(en)
|
2010-05-13 |
2013-03-20 |
Amgen Inc. |
Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
|
MX2012013127A
(es)
|
2010-05-13 |
2012-11-30 |
Amgen Inc |
Compuestos heteroariloxiheterociclilo como inhibidores pde10.
|
BR112012028920B1
(pt)
|
2010-05-14 |
2021-03-23 |
Amgen Inc. |
Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
|
WO2011146583A2
(en)
|
2010-05-19 |
2011-11-24 |
Elan Pharma International Limited |
Nanoparticulate cinacalcet formulations
|
HUP1000325A2
(en)
|
2010-06-18 |
2012-01-30 |
Druggability Technologies Ip Holdco Jersey Ltd |
Nanostructured aprepitant compositions and process for their preparation
|
KR20130117755A
(ko)
|
2010-06-21 |
2013-10-28 |
맨카인드 코포레이션 |
건조 분말 약물 운반 시스템 및 방법
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
EP3263111A1
(en)
|
2010-06-30 |
2018-01-03 |
Victoria Link Ltd |
Methods and compositions for treatment of multiple sclerosis
|
TW201244719A
(en)
|
2010-07-09 |
2012-11-16 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
WO2012009137A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
WO2012009134A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
US9358237B2
(en)
|
2010-07-23 |
2016-06-07 |
Demerx, Inc. |
Noribogaine compositions
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
AR082986A1
(es)
|
2010-09-14 |
2013-01-23 |
Exelixis Inc |
DERIVADOS DE PURINA COMO INHIBIDORES DE PI3K-d, METODOS PARA SU PREPARACION, FORMULACIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
|
ES2693257T3
(es)
|
2010-09-14 |
2018-12-10 |
Exelixis, Inc. |
Inhibidores de PI3K-delta y métodos para su uso y fabricación
|
EP2616443A1
(en)
|
2010-09-14 |
2013-07-24 |
Exelixis, Inc. |
Phtalazine derivatives as jak1 inhibitors
|
US8916610B2
(en)
|
2010-09-22 |
2014-12-23 |
Ramot At Tel-Aviv University Ltd. |
Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
|
CN103221049B
(zh)
|
2010-09-23 |
2015-11-25 |
诺弗米克斯有限公司 |
阿瑞匹坦l-脯氨酸组合物和共晶
|
US20140057943A1
(en)
|
2010-09-27 |
2014-02-27 |
Exelixix, Inc. |
Method of Treating Cancer
|
CN103391772A
(zh)
|
2010-09-27 |
2013-11-13 |
埃克塞里艾克西斯公司 |
用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
|
CN103391773A
(zh)
|
2010-09-27 |
2013-11-13 |
埃克塞里艾克西斯公司 |
用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
|
WO2012051426A2
(en)
*
|
2010-10-15 |
2012-04-19 |
Glaxo Group Limited |
Aggregate nanoparticulate medicament formulations, manufacture and use thereof
|
EP2635260A4
(en)
*
|
2010-11-02 |
2014-07-09 |
Univ Nebraska |
COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
WO2012061337A1
(en)
|
2010-11-02 |
2012-05-10 |
Exelixis, Inc. |
Fgfr2 modulators
|
WO2012065019A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of p13k alpha
|
WO2012065057A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
US20140066431A1
(en)
|
2010-11-15 |
2014-03-06 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
WO2012071509A2
(en)
|
2010-11-24 |
2012-05-31 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
MX2013006467A
(es)
|
2010-12-09 |
2013-10-01 |
Amgen Inc |
Compuestos biciclicos como inhibidores pim.
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2012083269A1
(en)
|
2010-12-16 |
2012-06-21 |
Cynapsus Therapeutics, Inc. |
Sublingual films
|
EP2658857B1
(en)
|
2010-12-29 |
2016-11-02 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
EP2661434A4
(en)
|
2011-01-06 |
2014-07-09 |
Beta Pharma Canada Inc |
NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
EP2688886A1
(en)
|
2011-03-22 |
2014-01-29 |
Amgen Inc. |
Azole compounds as pim inhibitors
|
BR112013024493A2
(pt)
|
2011-03-25 |
2018-06-26 |
Amgen Inc. |
cristais de anticorpo antiesclerostina e formulações dos mesmos
|
EP2694402B1
(en)
|
2011-04-01 |
2017-03-22 |
MannKind Corporation |
Blister package for pharmaceutical cartridges
|
LT2696848T
(lt)
|
2011-04-15 |
2020-09-10 |
Janssen Pharmaceutica N.V. |
Liofilizuotos vaisto nanosuspensijos
|
CN109517897A
(zh)
|
2011-04-28 |
2019-03-26 |
南加利福尼亚大学 |
人类髓源抑制性细胞癌症标记
|
JP2014516941A
(ja)
|
2011-04-29 |
2014-07-17 |
アムジェン インコーポレイテッド |
Pim阻害剤としての二環式ピリダジン化合物
|
JP2014513104A
(ja)
|
2011-04-29 |
2014-05-29 |
エクセリクシス, インク. |
Pi3k/mtorのピリドピリミジノン阻害剤を用いたリンパ腫の治療方法
|
WO2012154879A2
(en)
|
2011-05-09 |
2012-11-15 |
Van Andel Research Institute |
Autophagy inhibitors
|
US8709034B2
(en)
|
2011-05-13 |
2014-04-29 |
Broncus Medical Inc. |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
WO2012158553A2
(en)
|
2011-05-13 |
2012-11-22 |
Broncus Technologies, Inc. |
Methods and devices for excision of tissue
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
US9187487B2
(en)
|
2011-05-17 |
2015-11-17 |
Principia Biopharma, Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
EP3415139B8
(en)
|
2011-06-14 |
2022-05-18 |
Neurelis, Inc. |
Administration of benzodiazepine
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
MX2013013627A
(es)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Composiciones y metodos para la terapia y diagnostico de cancer.
|
JP5978296B2
(ja)
|
2011-06-28 |
2016-08-24 |
フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド |
抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
|
US8609653B2
(en)
|
2011-07-15 |
2013-12-17 |
Glaxosmithkline Llc |
Azaindole compounds and methods for treating HIV
|
HUE032747T2
(en)
|
2011-07-22 |
2017-10-30 |
Chemocentryx Inc |
Crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-oxypyridine-4-carbonyl) phenyl] benzenesulfonamide
|
JP6166721B2
(ja)
|
2011-07-22 |
2017-07-19 |
ケモセントリックス, インコーポレイテッド |
4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の多形
|
JP6301832B2
(ja)
|
2011-08-04 |
2018-03-28 |
アムジエン・インコーポレーテツド |
骨間隙欠陥を処置する方法
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
SG2014011886A
(en)
|
2011-09-01 |
2014-05-29 |
Glaxo Group Ltd |
Novel crystal form
|
TW201325592A
(zh)
|
2011-09-14 |
2013-07-01 |
Exelixis Inc |
用於治療癌症之磷脂醯肌醇-3激酶抑制劑
|
KR101794032B1
(ko)
|
2011-09-21 |
2017-11-07 |
(주)바이오시네틱스 |
나노입자 제조방법
|
ES2632443T3
(es)
|
2011-09-22 |
2017-09-13 |
Viiv Healthcare Uk Limited |
Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
MX340951B
(es)
|
2011-09-29 |
2016-07-29 |
Plx Pharma Inc |
Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas.
|
WO2013056067A1
(en)
|
2011-10-13 |
2013-04-18 |
Exelixis, Inc. |
Compounds for use in the treatment of basal cell carcinoma
|
TWI580442B
(zh)
*
|
2011-10-19 |
2017-05-01 |
傑特大學 |
醫藥毫微懸浮物
|
US9233159B2
(en)
|
2011-10-24 |
2016-01-12 |
Mannkind Corporation |
Methods and compositions for treating pain
|
BR112014010492A2
(pt)
|
2011-11-01 |
2017-04-25 |
Exelixis Inc |
n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
|
WO2013067306A1
(en)
|
2011-11-02 |
2013-05-10 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
|
CA2854336A1
(en)
|
2011-11-08 |
2013-05-16 |
Exelixis, Inc. |
Dual inhibitor of met and vegf for treating cancer
|
KR20140094597A
(ko)
|
2011-11-08 |
2014-07-30 |
엑셀리시스, 인코포레이티드 |
암 치료를 정량하는 방법
|
CN107011426B
(zh)
|
2011-11-11 |
2021-05-14 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
JP2015501802A
(ja)
|
2011-11-17 |
2015-01-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤
|
WO2013078235A1
(en)
|
2011-11-23 |
2013-05-30 |
Broncus Medical Inc |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
CN104159584A
(zh)
|
2011-11-25 |
2014-11-19 |
诺弗米克斯有限公司 |
阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
|
JP2015500833A
(ja)
|
2011-12-09 |
2015-01-08 |
デメレックス, インコーポレイテッド |
ノルイボガインのリン酸エステル
|
JO3387B1
(ar)
|
2011-12-16 |
2019-03-13 |
Glaxosmithkline Llc |
مشتقات بيتولين
|
EA202091676A1
(ru)
|
2011-12-28 |
2021-01-29 |
Эмджен Инк. |
Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
CA2858820C
(en)
|
2012-01-25 |
2021-08-17 |
Demerx, Inc. |
Synthetic voacangine
|
WO2013130660A1
(en)
|
2012-02-28 |
2013-09-06 |
Amgen Inc. |
Amides as pim inhibitors
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
RS59960B1
(sr)
|
2012-03-19 |
2020-03-31 |
Cidara Therapeutics Inc |
Dozni režimi za jedinjenja klase ehinokandina
|
EP2827853A1
(en)
|
2012-03-22 |
2015-01-28 |
Nanotherapeutics, Inc. |
Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
|
KR101956586B1
(ko)
*
|
2012-03-27 |
2019-03-11 |
일양약품주식회사 |
약제학적 조성물 및 이의 제조방법
|
WO2013148978A1
(en)
|
2012-03-30 |
2013-10-03 |
Lexicon Pharmaceuticals, Inc. |
Methods and compositions for the treatment of necrotizing enterocolitis
|
US20150080381A1
(en)
|
2012-04-12 |
2015-03-19 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
US9452107B2
(en)
|
2012-04-16 |
2016-09-27 |
New Jersey Institute Of Technology |
Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
|
US9861624B2
(en)
|
2012-05-02 |
2018-01-09 |
Exelixis, Inc. |
Method of treating cancer
|
EP2844295A1
(en)
|
2012-05-03 |
2015-03-11 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
KR102154880B1
(ko)
|
2012-05-03 |
2020-09-10 |
칼라 파마슈티컬스, 인크. |
개선된 점막 수송을 나타내는 제약 나노입자
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
BR112014028431B1
(pt)
|
2012-05-11 |
2022-01-11 |
Activus Pharma Co., Ltd |
Nanopó de composto orgânico, método para produzir o mesmo e suspensão
|
CN118453592A
(zh)
|
2012-05-17 |
2024-08-09 |
Vtv治疗有限责任公司 |
用于治疗糖尿病的葡萄糖激酶活化剂组合物
|
KR20190040370A
(ko)
|
2012-06-04 |
2019-04-17 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
UY34858A
(es)
|
2012-06-14 |
2013-11-29 |
Amgen Inc |
Compuestos de azetidina y piperidina útiles como inhibidores de pde10
|
EP3597178A1
(en)
|
2012-06-21 |
2020-01-22 |
Phosphorex Inc. |
Nanoparticles of indirubin, derivatives thereof and methods of making and using same
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
EP3626267A1
(en)
|
2012-07-05 |
2020-03-25 |
UCB Pharma, S.A. |
Treatment for bone diseases
|
EP2877468B1
(en)
|
2012-07-12 |
2017-08-23 |
ViiV Healthcare UK Limited |
Compounds and methods for treating hiv
|
AU2013289957B2
(en)
|
2012-07-12 |
2017-02-23 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
JOP20130213B1
(ar)
|
2012-07-17 |
2021-08-17 |
Takeda Pharmaceuticals Co |
معارضات لمستقبلht3-5
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
WO2014028479A1
(en)
|
2012-08-13 |
2014-02-20 |
Envoy Therapeutics, Inc. |
Quinoxaline derivatives as gpr6 modulators
|
JP2015527372A
(ja)
|
2012-08-22 |
2015-09-17 |
ゼノポート,インコーポレイティド |
副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
|
CA2882730C
(en)
|
2012-08-22 |
2019-12-31 |
Xenoport, Inc. |
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2890691B1
(en)
|
2012-08-31 |
2018-04-25 |
Principia Biopharma Inc. |
Benzimidazole derivatives as itk inhibitors
|
WO2014036528A2
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
SG11201501815UA
(en)
|
2012-09-10 |
2015-05-28 |
Principia Biopharma Inc |
Pyrazolopyrimidine compounds as kinase inhibitors
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
SG11201503977PA
(en)
|
2012-11-20 |
2015-06-29 |
Principia Biopharma Inc |
Azaindole derivatives as jak3 inhibitors
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
US9546174B2
(en)
|
2012-11-30 |
2017-01-17 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (IAP) antagonists
|
WO2014091318A1
(en)
|
2012-12-11 |
2014-06-19 |
Lupin Atlantis Holdings, S.A. |
Reduced dose pharmaceutical compositions of fenofibrate
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
CA2896133A1
(en)
|
2012-12-20 |
2014-06-26 |
Demerx, Inc. |
Substituted noribogaine
|
EP2951205B1
(en)
|
2013-02-01 |
2021-08-11 |
Santa Maria Biotherapeutics, Inc. |
Anti-activin-a compounds for the treatment of ovarian cancer
|
JP2016508447A
(ja)
*
|
2013-02-28 |
2016-03-22 |
サン・ケミカル・コーポレーション |
連続的微細メディア含有粉砕プロセス
|
JP6441828B2
(ja)
*
|
2013-03-04 |
2018-12-19 |
ブイティーブイ・セラピューティクス・エルエルシー |
安定なグルコキナーゼ活性化剤組成物
|
WO2014160177A2
(en)
|
2013-03-13 |
2014-10-02 |
Exelixis, Inc. |
Quinazoline inhibitors of pi3k
|
US9732068B1
(en)
|
2013-03-15 |
2017-08-15 |
GenSyn Technologies, Inc. |
System for crystalizing chemical compounds and methodologies for utilizing the same
|
CA2905162A1
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
|
MX369136B
(es)
|
2013-03-15 |
2019-10-30 |
Mannkind Corp |
Composiciones de dicetopiperazina microcristalina y metodos.
|
WO2014160633A1
(en)
|
2013-03-24 |
2014-10-02 |
Xenoport, Inc. |
Pharmaceutical compositions of dimethyl fumarate
|
HUE041709T2
(hu)
|
2013-04-05 |
2019-05-28 |
Boehringer Ingelheim Int |
Az empagliflozin terápiás alkalmazásai
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AU2014255727B2
(en)
|
2013-04-18 |
2019-07-25 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CA2911706A1
(en)
|
2013-05-09 |
2014-11-13 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor inhibitors
|
WO2014197860A1
(en)
|
2013-06-07 |
2014-12-11 |
Xenoport, Inc. |
Method of making monomethyl fumarate
|
JP2016522251A
(ja)
|
2013-06-20 |
2016-07-28 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
Trpa1アンタゴニストを含むナノ粒子製剤
|
US9421182B2
(en)
|
2013-06-21 |
2016-08-23 |
Xenoport, Inc. |
Cocrystals of dimethyl fumarate
|
KR102465025B1
(ko)
|
2013-07-18 |
2022-11-09 |
맨카인드 코포레이션 |
열-안정성 건조 분말 약제학적 조성물 및 방법
|
US11446127B2
(en)
|
2013-08-05 |
2022-09-20 |
Mannkind Corporation |
Insufflation apparatus and methods
|
TW201516020A
(zh)
|
2013-09-06 |
2015-05-01 |
Xenoport Inc |
(n,n-二乙基胺甲醯基)甲基(2e)丁-2-烯-1,4-二酸甲酯之晶形、合成方法及用途
|
WO2015042294A1
(en)
|
2013-09-18 |
2015-03-26 |
Xenoport, Inc. |
Nanoparticle compositions of dimethyl fumarate
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
EP2878311A1
(en)
|
2013-11-27 |
2015-06-03 |
Freund Pharmatec Ltd. |
Solubility Enhancement for Hydrophobic Drugs
|
WO2015106025A1
(en)
|
2014-01-09 |
2015-07-16 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Substituted benzoxazine and related compounds
|
WO2015108945A2
(en)
|
2014-01-14 |
2015-07-23 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
US10898581B2
(en)
|
2014-01-16 |
2021-01-26 |
The Brigham And Women's Hospital, Inc. |
Targeted delivery of immunoregulatory drugs
|
US10092569B2
(en)
|
2014-02-21 |
2018-10-09 |
Principia Biopharma Inc. |
Salts and solid form of a BTK inhibitor
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
US20150250776A1
(en)
|
2014-03-05 |
2015-09-10 |
Nanotherapeutics, Inc. |
Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
|
US9999672B2
(en)
|
2014-03-24 |
2018-06-19 |
Xenoport, Inc. |
Pharmaceutical compositions of fumaric acid esters
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
JP6696908B2
(ja)
|
2014-04-25 |
2020-05-20 |
エグゼリクシス, インコーポレイテッド |
肺腺癌の治療方法
|
TW201625247A
(zh)
|
2014-05-12 |
2016-07-16 |
葛蘭素史密斯克藍智慧財產權有限公司 |
用於治療傳染性疾病之醫藥組合物
|
WO2015187998A2
(en)
|
2014-06-04 |
2015-12-10 |
Sanford-Burnham Medical Research Institute |
Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
CA2989550C
(en)
|
2014-06-18 |
2023-08-08 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
US10654843B2
(en)
|
2014-06-20 |
2020-05-19 |
Principia Biopharma Inc. |
LMP7 inhibitors
|
SG11201610709UA
(en)
|
2014-06-25 |
2017-01-27 |
Glaxosmithkline Ip Dev Ltd |
Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
|
WO2016016861A1
(en)
|
2014-08-01 |
2016-02-04 |
Glenmark Pharmaceuticals S.A. |
Nanoparticulate formulation comprising a mpges-1 inhibitor
|
US10016415B2
(en)
|
2014-08-18 |
2018-07-10 |
Alkermes Pharma Ireland Limited |
Aripiprazole prodrug compositions
|
MX371417B
(es)
*
|
2014-08-18 |
2020-01-29 |
Alkermes Pharma Ireland Ltd |
Composiciones de profarmacos de aripiprazol.
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
US10987308B2
(en)
|
2014-09-03 |
2021-04-27 |
Genesegues, Inc. |
Therapeutic nanoparticles and related compositions, methods and systems
|
BR112017004673A2
(pt)
|
2014-09-08 |
2017-12-05 |
Glaxosmithkline Ip Dev Ltd |
formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
|
CN106795172B
(zh)
|
2014-09-29 |
2020-07-28 |
武田药品工业株式会社 |
1-(1-甲基-1h-吡唑-4-基)-n-((1r,5s,7s)-9-甲基-3-氧杂-9-氮杂双环[3.3.1]壬-7-基)-1h-吲哚-3-甲酰胺的晶型
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
EP3203995A4
(en)
|
2014-10-09 |
2019-05-15 |
Board of Regents of the University of Nebraska |
COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
|
SI3215127T1
(sl)
|
2014-11-07 |
2021-03-31 |
Sublimity Therapeutics Limited DCU Alpha Innovation Campus |
Sestavki, obsegajoči ciklosporin
|
TW201628610A
(zh)
*
|
2014-11-25 |
2016-08-16 |
奈諾生技公司 |
醫藥組合物、其製備及其用途
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CA2973109A1
(en)
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
CN104587457B
(zh)
*
|
2015-01-13 |
2017-03-22 |
广东海大畜牧兽医研究院有限公司 |
一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
EP3258918A1
(en)
|
2015-02-20 |
2017-12-27 |
Cytec Industries Inc. |
Dialkyl sulfosuccinate compositions, method of making, and method of use
|
CN107427498A
(zh)
|
2015-03-03 |
2017-12-01 |
药品循环有限责任公司 |
布鲁顿氏酪氨酸激酶抑制剂的医药配方
|
EP3274053A4
(en)
|
2015-03-23 |
2018-12-05 |
The Brigham and Women's Hospital, Inc. |
Tolerogenic nanoparticles for treating diabetes mellitus
|
EP3285771A4
(en)
|
2015-04-21 |
2018-12-05 |
Sunovion Pharmaceuticals Inc. |
Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
WO2016191172A1
(en)
|
2015-05-22 |
2016-12-01 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
PL3303334T3
(pl)
|
2015-06-03 |
2021-11-08 |
Principia Biopharma Inc. |
Inhibitory kinaz tyrozynowych
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2017004610A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Tercyclic s1p3-sparing, s1p1 receptor agonists
|
WO2017004609A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Thiadiazole modulators of s1p and methods of making and using
|
CA2990335A1
(en)
|
2015-07-02 |
2017-01-05 |
Glaxosmithkline Intellectual Property Development Limited |
Inhibitors of indoleamine 2,3-dioxygenase
|
WO2017004608A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Oxadiazole modulators of s1p methods of making and using
|
CA2993753A1
(en)
|
2015-07-28 |
2017-02-02 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Betuin derivatives for preventing or treating hiv infections
|
AU2016298667A1
(en)
|
2015-07-28 |
2018-02-22 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Betuin derivatives for preventing or treating HIV infections
|
EP3353167B1
(en)
|
2015-09-24 |
2020-06-24 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
WO2017051354A1
(en)
|
2015-09-24 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
CN108368071A
(zh)
|
2015-09-24 |
2018-08-03 |
葛兰素史克知识产权第二有限公司 |
具有hiv成熟抑制活性的化合物
|
MX2018004376A
(es)
|
2015-10-16 |
2018-08-01 |
Marinus Pharmaceuticals Inc |
Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
|
WO2017130156A1
(en)
|
2016-01-27 |
2017-08-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Ingenol analogs, pharmaceutical compositions and methods of use thereof
|
EP3416616B1
(en)
|
2016-02-17 |
2021-08-04 |
Alkermes Pharma Ireland Limited |
Compositions of multiple aripiprazole prodrugs
|
US11254651B2
(en)
|
2016-02-17 |
2022-02-22 |
Global Blood Therapeutics, Inc. |
Histone methyltransferase inhibitors
|
WO2017156071A1
(en)
|
2016-03-09 |
2017-09-14 |
Blade Therapeutics, Inc. |
Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
CN109310680B
(zh)
|
2016-06-30 |
2022-11-01 |
度瑞公司 |
长效配制物
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
TW201811376A
(zh)
|
2016-07-01 |
2018-04-01 |
英商葛蘭素史密斯克藍智慧財產權有限公司 |
抗體-藥物結合物及使用其之治療方法
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
WO2018031748A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
CN109803652A
(zh)
|
2016-08-19 |
2019-05-24 |
阿拉西斯医药公司 |
眼科药物组合物及其相关用途
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
JP7086942B2
(ja)
|
2016-09-12 |
2022-06-20 |
インテグラル ヘルス, インコーポレイテッド |
Gpr120モジュレーターとして有用な単環式化合物
|
PL3513809T3
(pl)
|
2016-09-13 |
2022-07-04 |
Kyowa Kirin Co., Ltd. |
Kompozycja lecznicza zawierająca tiwozanib
|
CN110023304A
(zh)
|
2016-09-28 |
2019-07-16 |
布莱德治疗公司 |
钙蛋白酶调节剂及其治疗用途
|
WO2018069200A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Dsm Ip Assets B.V. |
Preparation of nano-sized uv absorbers
|
EP3544614A4
(en)
|
2016-11-28 |
2020-08-05 |
Lipocine Inc. |
ORAL TESTOSTERONE UNDECANOATE THERAPY
|
CN110545669A
(zh)
|
2016-12-16 |
2019-12-06 |
科佩斯性能化学股份有限公司 |
木材防腐剂及其生产方法
|
TW201829386A
(zh)
|
2016-12-22 |
2018-08-16 |
美商全球血液治療公司 |
組蛋白甲基轉移酶抑制劑
|
MX2019008436A
(es)
|
2017-01-18 |
2019-09-18 |
Principia Biopharma Inc |
Inhibidores del inmunoproteasoma.
|
WO2018191277A1
(en)
|
2017-04-10 |
2018-10-18 |
Sierra Oncology, Inc. |
Chk1 (sra737)/parpi combination methods of inhibiting tumor growth
|
WO2018191418A1
(en)
|
2017-04-11 |
2018-10-18 |
Saje Pharma, Llc |
Carbazole compounds and methods of use thereof
|
EP3613415B1
(en)
|
2017-04-21 |
2022-11-09 |
Bio-Synectics Inc. |
Method for preparing active material nanoparticles using lipid as lubricant for milling
|
EP3634962B1
(en)
|
2017-06-09 |
2023-05-24 |
Global Blood Therapeutics, Inc. |
Azaindole compounds as histone methyltransferase inhibitors
|
LT3651736T
(lt)
|
2017-07-14 |
2021-10-11 |
Janssen Pharmaceutica Nv |
Ilgai veikiančios kompozicijos
|
WO2019036384A1
(en)
|
2017-08-15 |
2019-02-21 |
Global Blood Therapeutics, Inc. |
TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
|
EP3668863A1
(en)
|
2017-08-15 |
2020-06-24 |
Global Blood Therapeutics, Inc. |
Tricyclic compounds as histone methyl-transferase inhibitors
|
US11274102B2
(en)
|
2017-10-30 |
2022-03-15 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in HIV therapy
|
RS63666B1
(sr)
|
2017-11-16 |
2022-11-30 |
Principia Biopharma Inc |
Inhibitori imunoproteazoma
|
MA50906A
(fr)
|
2017-11-16 |
2020-09-23 |
Principia Biopharma Inc |
Inhibiteurs d'immunoprotéasome
|
WO2019140365A1
(en)
|
2018-01-12 |
2019-07-18 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
DE102018103528A1
(de)
|
2018-02-16 |
2019-08-22 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
|
WO2019169029A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Target specific chemotherapeutic agents
|
WO2019169017A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Chemotherapeutic agents
|
EP3762104A2
(en)
*
|
2018-03-07 |
2021-01-13 |
ST IP Holding AG |
Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
|
JP2021515771A
(ja)
|
2018-03-07 |
2021-06-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
Hiv療法に有用な化合物
|
CA3093457A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
WO2019199756A1
(en)
|
2018-04-09 |
2019-10-17 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
CN112236141A
(zh)
|
2018-06-11 |
2021-01-15 |
大塚制药株式会社 |
包含德拉马尼的组合物
|
AU2019287437A1
(en)
|
2018-06-12 |
2020-09-10 |
Vtv Therapeutics Llc |
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
|
CA3108635A1
(en)
|
2018-08-09 |
2020-02-13 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Compounds useful in hiv therapy
|
EP3844164A1
(en)
|
2018-08-30 |
2021-07-07 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Compounds useful in hiv therapy
|
WO2020121006A2
(en)
|
2018-10-19 |
2020-06-18 |
Innostudio Inc. |
Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
|
ES2968538T3
(es)
|
2018-11-30 |
2024-05-10 |
Glaxosmithkline Ip Dev Ltd |
Compuestos útiles en la terapia del VIH
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
WO2020154420A2
(en)
|
2019-01-22 |
2020-07-30 |
The Roskamp Institute |
Amino acid derivatives for the treatment of inflammatory diseases
|
WO2020167912A1
(en)
|
2019-02-13 |
2020-08-20 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
TW202102233A
(zh)
|
2019-03-06 |
2021-01-16 |
英商葛蘭素史密斯克藍智慧財產權有限公司 |
用於hiv治療之化合物
|
US12029744B2
(en)
|
2019-04-12 |
2024-07-09 |
Riboscience Llc |
Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
JP2022543319A
(ja)
|
2019-08-08 |
2022-10-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド |
Hiv治療に有用な化合物
|
WO2021038509A1
(en)
|
2019-08-28 |
2021-03-04 |
Glaxosmithkline Intellectual Property (No.2) Limited |
4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
|
EP4041223A4
(en)
|
2019-10-11 |
2023-10-18 |
Corbus Pharmaceuticals, Inc. |
AJULEMIC ACID COMPOSITIONS AND THEIR USES
|
IL293525A
(en)
|
2019-12-06 |
2022-08-01 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in the treatment of multiple sclerosis complex
|
WO2021150476A1
(en)
|
2020-01-20 |
2021-07-29 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
|
EP4125820A4
(en)
|
2020-03-26 |
2024-04-10 |
PLx Opco Inc. |
PHARMACEUTICAL CARRIERS CAPABLE OF PH-DEPENDENT RECONSTITUTION AND METHODS OF PREPARATION AND USE THEREOF
|
CA3173330A1
(en)
|
2020-04-17 |
2021-10-21 |
Genzyme Corporation |
Eclitasertib for use in treating conditions involving systemichyperinflammatory response
|
KR20230015346A
(ko)
|
2020-04-22 |
2023-01-31 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제를 사용하는 급성 호흡 곤란 증후군 및 시토카인 폭풍을 수반하는 다른 장애의 치료
|
EP3928772B1
(en)
|
2020-06-26 |
2024-06-19 |
Algiax Pharmaceuticals GmbH |
Nanoparticulate composition
|
US20230355606A1
(en)
|
2020-07-09 |
2023-11-09 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
AU2021303490A1
(en)
|
2020-07-09 |
2023-03-09 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
CN115776881A
(zh)
|
2020-07-09 |
2023-03-10 |
詹森药业有限公司 |
长效配制品
|
US11980636B2
(en)
|
2020-11-18 |
2024-05-14 |
Jazz Pharmaceuticals Ireland Limited |
Treatment of hematological disorders
|
CN112451520B
(zh)
*
|
2020-12-31 |
2021-10-15 |
江苏宇锐医药科技有限公司 |
一种缬沙坦氨氯地平组合物及其制备方法
|
JP2024507550A
(ja)
|
2021-02-23 |
2024-02-20 |
ヴィーブ、ヘルスケア、カンパニー |
Hiv療法に有用な化合物
|
WO2023023473A1
(en)
|
2021-08-16 |
2023-02-23 |
Sierra Oncology, Inc. |
Methods of using momelotinib to treat chronic kidney disease
|
CA3230398A1
(en)
*
|
2021-08-31 |
2023-03-09 |
Natsar Pharmaceuticals, Inc. |
Intravenous formulations of rk-33
|
WO2023239727A1
(en)
|
2022-06-06 |
2023-12-14 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Lats inhibitors and uses thereof
|
WO2023244672A1
(en)
|
2022-06-14 |
2023-12-21 |
Assembly Biosciences, Inc. |
2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
|
WO2024006406A1
(en)
|
2022-06-30 |
2024-01-04 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
|
WO2024010782A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
TW202408487A
(zh)
|
2022-07-06 |
2024-03-01 |
美商維維迪昂醫療公司 |
包含wrn解旋酶抑制劑之醫藥組成物
|
WO2024068699A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
WO2024068693A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
WO2024081168A1
(en)
|
2022-10-11 |
2024-04-18 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis
|
CN115844821B
(zh)
*
|
2023-01-03 |
2024-05-17 |
江苏知原药业股份有限公司 |
一种地奈德纳米晶混悬液、制备方法及其应用
|